1	hsa-mir-143	ERK5	Obesity	16195701	Modified oligonucleotide complementary to miR-143 effectively suppressed adipocyte differentiation by modulation of its putative target ERK5, a protein previously known to be implicated in MAP kinase signaling pathways.
2	hsa-mir-122	CAT-1	Carcinoma, Hepatocellular	16777601	inhibite CAT-1
3	hsa-mir-20a	TGFBR2	Breast Neoplasms	17011485	TGF-b-2 receptor is expressed in the epithelium of breast cancer and can be regulated by miR-20a, which is down- regulated in breast cancer.
4	hsa-mir-22	KIT	Thyroid Neoplasms	17012848	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
5	hsa-mir-16-1	BCL2	Leukemia, Lymphocytic, Chronic, B-Cell	17012848	It was found that mir-16-1 and mir-15a at 13q14 are deleted in more than 50% patients, with concurrent reduced expression in ~65% patients. Further studies demonstrated that these two miRNAs suppress BCL2 expression and may serve as tumor suppressor genes
6	hsa-mir-127	BCL6	Neoplasms	17012848	For example, mir-127, which is generally expressed in normal cells but absent in cancer cells, was markedly induced after treatment. Intriguingly, a predicted target of mir-127, BCL6, was translationally downregulated after treatment.
7	hsa-mir-221	KIT	Thyroid Neoplasms	17012848	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
8	hsa-mir-146b	KIT	Thyroid Neoplasms	17012848	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
9	hsa-mir-15a	BCL2	Leukemia, Lymphocytic, Chronic, B-Cell	17012848	It was found that mir-16-1 and mir-15a at 13q14 are deleted in more than 50% patients, with concurrent reduced expression in ~65% patients. Further studies demonstrated that these two miRNAs suppress BCL2 expression and may serve as tumor suppressor genes
10	hsa-mir-146a	KIT	Thyroid Neoplasms	17012848	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
11	hsa-mir-19a	PTEN	Carcinoma, Hepatocellular	17188425	miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN.
12	hsa-mir-19b-2	PTEN	Carcinoma, Hepatocellular	17188425	miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN.
13	hsa-mir-200a	RAB30	Carcinoma, Hepatocellular	17188425	Integration at FRA1A may silence expression of miRNA-200a, which is known to be decreased in HCC compared to nontumor [59] and [65]. Since most miRNAs suppress their target proteins, and miRNA-200a is known to regulate the expression of RAB30, a member of
14	hsa-mir-224	PDGFR	Hepatitis, Chronic	17188425	miRNA-224 regulates PDGFR expression, and decreases as disease progresses from chronic hepatitis to cirrhosis [59], suggesting that miRNA normally suppresses PDGFR in the liver until HBV integration and genetic instability upsets this balance. miRNA-224 a
15	hsa-mir-19b-1	PTEN	Carcinoma, Hepatocellular	17188425	miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN.
16	hsa-let-7f-1	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
17	hsa-let-7c	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
18	hsa-let-7f-2	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
19	hsa-let-7i	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
20	hsa-let-7b	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
21	hsa-let-7a-2	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
22	hsa-let-7g	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
23	hsa-let-7a-3	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
24	hsa-let-7a-1	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
25	hsa-let-7e	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
26	hsa-let-7d	Hmga2	Neoplasms	17322030	Disrupting the pairing between let-7 and Hmga2
27	hsa-mir-24-1	SLITRK1	Tourette Syndrome	17462786	A mutation in the 3'UTR of the SLITRK1 gene which is associated with Tourette's syndrome was found to enhance repression of the SLITRK mRNA by miR-189, presumably preventing SLITRK1's promotion of dendritic growth.
28	hsa-mir-221	KIT	Thyroid Neoplasms	17468766	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3?? UTR of the KIT oncogene in papillary thyroid carcinoma.
29	hsa-mir-146b	KIT	Thyroid Neoplasms	17468766	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3?? UTR of the KIT oncogene in papillary thyroid carcinoma.
30	hsa-mir-222	KIT	Thyroid Neoplasms	17468766	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3?? UTR of the KIT oncogene in papillary thyroid carcinoma.
31	hsa-mir-146a	KIT	Thyroid Neoplasms	17468766	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3?? UTR of the KIT oncogene in papillary thyroid carcinoma.
32	hsa-mir-103a-2	DMPK	Myotonic Dystrophy	17697356	These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK.
33	hsa-mir-103a-1	DMPK	Myotonic Dystrophy	17697356	These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK.
34	hsa-mir-107	DMPK	Myotonic Dystrophy	17697356	These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK.
35	hsa-mir-29c	DNMT3A	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
36	hsa-mir-29c	DNMT3b	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
37	hsa-mir-29a	DNMT3A	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
38	hsa-mir-29a	DNMT3b	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
39	hsa-mir-29b-1	DNMT3A	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
40	hsa-mir-29b-1	DNMT3b	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
41	hsa-mir-133a-1	ERG	Arrhythmias, Cardiac	17965831	miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model.
42	hsa-mir-29b-1	TCL1	Neoplasms	17965831	Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163]
43	hsa-mir-29b-2	TCL1	Neoplasms	17965831	Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163]
44	hsa-mir-181b	TCL1	Neoplasms	17965831	Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163]
45	hsa-let-7i	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
46	hsa-let-7b	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
47	hsa-let-7e	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
48	hsa-let-7f-1	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
49	hsa-let-7d	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
50	hsa-let-7c	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
51	hsa-let-7a-3	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
52	hsa-let-7i	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
53	hsa-let-7b	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
54	hsa-let-7e	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
55	hsa-let-7f-1	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
56	hsa-let-7d	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
57	hsa-let-7c	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
58	hsa-let-7a-3	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
59	hsa-mir-373	LATS2	Neoplasms	17989227	the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2.
60	hsa-mir-372	LATS2	Neoplasms	17989227	the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2.
61	hsa-let-7a-2	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
62	hsa-let-7f-2	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
63	hsa-let-7a-1	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
64	hsa-let-7g	Hmg2A	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
65	hsa-let-7a-2	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
66	hsa-let-7f-2	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
67	hsa-let-7a-1	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
68	hsa-let-7g	RAS	Neoplasms	17989227	let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
69	hsa-mir-433	FGF20	Parkinson Disease	18252210	Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.
70	hsa-mir-124-1	CDK6	Medulloblastoma	18607543	miR-124: regulates cyclin dependent kinase 6
71	hsa-mir-124-2	CDK6	Medulloblastoma	18607543	miR-124: regulates cyclin dependent kinase 6
72	hsa-mir-124-3	CDK6	Medulloblastoma	18607543	miR-124: regulates cyclin dependent kinase 6
73	hsa-mir-451a	MDR	Neoplasms	18619946	miR-451: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein
74	hsa-mir-27a	MDR	Neoplasms	18619946	miR-27a: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein
75	hsa-mir-451a	ABCB1	Neoplasms	18619946	miR-451: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein
76	hsa-mir-27a	ABCB1	Neoplasms	18619946	miR-27a: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein
77	hsa-let-7f-1	ITGB3	Melanoma	18679415	let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
78	hsa-let-7a-2	ITGB3	Melanoma	18679415	let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
79	hsa-let-7b	ITGB3	Melanoma	18679415	let-7b: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
80	hsa-let-7a-1	ITGB3	Melanoma	18679415	let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
81	hsa-let-7i	ITGB3	Melanoma	18679415	let-7i: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
82	hsa-let-7a-3	ITGB3	Melanoma	18679415	let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
83	hsa-let-7d	ITGB3	Melanoma	18679415	let-7d: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
84	hsa-let-7c	ITGB3	Melanoma	18679415	let-7c: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
85	hsa-let-7g	ITGB3	Melanoma	18679415	let-7g: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
86	hsa-let-7e	ITGB3	Melanoma	18679415	let-7e: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
87	hsa-let-7f-2	ITGB3	Melanoma	18679415	let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
88	hsa-mir-659	GRN	Dementia	18723524	miR-659: Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia
89	hsa-let-7a-1	CASP3	Neoplasms	18758960	Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
90	hsa-let-7a-2	CASP3	Neoplasms	18758960	Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
91	hsa-let-7a-3	CASP3	Neoplasms	18758960	Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
92	hsa-mir-302b	CCND2	Carcinoma, Embryonal	18930031	miR-302b: "miR-302b maintains ""stemness"" of human embryonal carcinoma cells by post-transcriptional regulation of Cyclin D2 expression"
93	hsa-mir-15a	Cdc25A	Polycystic Kidney Diseases	18949056	miR-15a: MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis
94	hsa-mir-21	PDCD4	Glioblastoma	19013014	miR-21: MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G
95	hsa-mir-29a	CDC42	Neoplasms	19079265	miR-29a: miR-29 directly suppress p85 alpha and CDC42, both of which negatively regulate p53
96	hsa-mir-29a	PIK3R1	Neoplasms	19079265	miR-29a: miR-29 directly suppress p85 alpha and CDC42, both of which negatively regulate p53
97	hsa-mir-15a	CCNE1	Head and Neck Neoplasms	19117988	miR-15a: feed-forward loop: PKCalpha down-regulates miR-15a, which directly inhibits protein synthesis of cyclin E
98	hsa-mir-15a	CCNE2	Head and Neck Neoplasms	19117988	miR-15a: feed-forward loop: PKCalpha down-regulates miR-15a, which directly inhibits protein synthesis of cyclin E
99	hsa-mir-221	cKit	Melanoma	19126397	miR-221: mir-221 can directly interact with c-kit 3'UTR and inhibit cKit protein translation
100	hsa-mir-1-2	PP2A	Arrhythmias, Cardiac	19131648	miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2
101	hsa-mir-1-1	PP2A	Arrhythmias, Cardiac	19131648	miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2
102	hsa-mir-101-1	FOS	Carcinoma, Hepatocellular	19133651	miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene
103	hsa-mir-101-2	FOS	Carcinoma, Hepatocellular	19133651	miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene
104	hsa-mir-93	p21	Stomach Neoplasms	19153141	miR-93: inhibite p21,p27, and p57
105	hsa-mir-93	p27	Stomach Neoplasms	19153141	miR-93: inhibite p21,p27, and p57
106	hsa-mir-93	p57	Stomach Neoplasms	19153141	miR-93: inhibite p21,p27, and p57
107	hsa-mir-222	p21	Stomach Neoplasms	19153141	miR-222: inhibite p21,p27, and p57
108	hsa-mir-222	p27	Stomach Neoplasms	19153141	miR-222: inhibite p21,p27, and p57
109	hsa-mir-222	p57	Stomach Neoplasms	19153141	miR-222: inhibite p21,p27, and p57
110	hsa-mir-221	p21	Stomach Neoplasms	19153141	miR-221: inhibite p21,p27, and p57
111	hsa-mir-221	p27	Stomach Neoplasms	19153141	miR-221: inhibite p21,p27, and p57
112	hsa-mir-221	p57	Stomach Neoplasms	19153141	miR-221: inhibite p21,p27, and p57
113	hsa-mir-25	p21	Stomach Neoplasms	19153141	miR-25: inhibite p21,p27, and p57
114	hsa-mir-25	p27	Stomach Neoplasms	19153141	miR-25: inhibite p21,p27, and p57
115	hsa-mir-25	p57	Stomach Neoplasms	19153141	miR-25: inhibite p21,p27, and p57
116	hsa-mir-106b	p21	Stomach Neoplasms	19153141	miR-106b: inhibite p21,p27, and p57
117	hsa-mir-106b	p27	Stomach Neoplasms	19153141	miR-106b: inhibite p21,p27, and p57
118	hsa-mir-106b	p57	Stomach Neoplasms	19153141	miR-106b: inhibite p21,p27, and p57
119	hsa-mir-141	CDH1	Neoplasms	19182522	miR-141: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
120	hsa-mir-141	ZEB1	Neoplasms	19182522	miR-141: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
121	hsa-mir-141	ZEB2	Neoplasms	19182522	miR-141: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
122	hsa-mir-200b	CDH1	Neoplasms	19182522	miR-200b: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
123	hsa-mir-200b	ZEB1	Neoplasms	19182522	miR-200b: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
124	hsa-mir-200b	ZEB2	Neoplasms	19182522	miR-200b: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
125	hsa-mir-200c	CDH1	Neoplasms	19182522	miR-200c: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
126	hsa-mir-200c	ZEB1	Neoplasms	19182522	miR-200c: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
127	hsa-mir-200c	ZEB2	Neoplasms	19182522	miR-200c: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
128	hsa-mir-200a	CDH1	Neoplasms	19182522	miR-200a: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
129	hsa-mir-200a	ZEB1	Neoplasms	19182522	miR-200a: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
130	hsa-mir-200a	ZEB2	Neoplasms	19182522	miR-200a: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
131	hsa-mir-429	CDH1	Neoplasms	19182522	miR-429: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
132	hsa-mir-429	ZEB1	Neoplasms	19182522	miR-429: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
133	hsa-mir-429	ZEB2	Neoplasms	19182522	miR-429: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
134	hsa-mir-1-2	CAMK2G	Cardiomegaly	19188439	miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
135	hsa-mir-1-2	Mef2a	Cardiomegaly	19188439	miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
136	hsa-mir-1-1	CAMK2G	Cardiomegaly	19188439	miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
137	hsa-mir-1-1	Mef2a	Cardiomegaly	19188439	miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
138	hsa-mir-182	FOXO3	Melanoma	19188590	miR-182: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor
139	hsa-mir-18b	BTG2	Carcinoma, Hepatocellular	19203451	miR-18: target BTG2
140	hsa-mir-18a	BTG2	Carcinoma, Hepatocellular	19203451	miR-18: target BTG2
141	hsa-mir-10a	Hoxd4	Breast Neoplasms	19232136	miR-10a: miR-10a inhibits transcriptional of Hoxd4
142	hsa-mir-34b	CREB1	Leukemia, Myeloid, Acute	19258499	miR-34b: miR-34b targets cyclic AMP-responsive element binding protein
143	hsa-mir-101-1	EZH2	Urinary Bladder Neoplasms	19258506	miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2
144	hsa-mir-101-2	EZH2	Urinary Bladder Neoplasms	19258506	miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2
145	hsa-mir-222	p27Kip1	Marek Disease	19264608	miR-222: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1
146	hsa-mir-221	p27Kip1	Marek Disease	19264608	miR-221: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1
147	hsa-mir-21	MARCKS	Prostatic Neoplasms	19302977	miR-21: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells
148	hsa-mir-21	PDCD4	Myocardial Infarction	19336275	miR-21: miR-21 can protect this by targeting PDCD4
149	hsa-mir-21	PDCD4	Cardiomyopathy, Hypertrophic	19336275	miR-21: miR-21 can protect this by targeting PDCD4
150	hsa-mir-21	PDCD4	Myocardial Reperfusion Injury	19336275	miR-21: miR-21 can protect this by targeting PDCD4
151	hsa-mir-21	PDCD4	Heart Failure	19336275	miR-21: miR-21 can protect this by targeting PDCD4
152	hsa-mir-21	PDCD4	Myocardial Ischemia	19336275	miR-21: miR-21 can protect this by targeting PDCD4
153	hsa-mir-21	PDCD4	Myocytes, Cardiac	19336275	MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4
154	hsa-mir-92a-1	VHL	Leukemia, Lymphocytic, Chronic, B-Cell	19336759	miR-92-1: overexpressed, can target the VHL transcript
155	hsa-mir-145	PDGFD	Prostatic Neoplasms	19544444	regulates PDGF-D, which mediate epithelial-mesenchymal transition, adhesion, and invasion, which was associated with the downregulation of ZEB1, ZEB2,and Snail2 expression;
156	hsa-mir-429	EP300	Adenocarcinoma	19569050	regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;
157	hsa-mir-200c	EP300	Adenocarcinoma	19569050	regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;
158	hsa-mir-200b	EP300	Adenocarcinoma	19569050	regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;
159	hsa-mir-31	FOXO1	Breast Neoplasms	19574223	Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells
160	hsa-mir-182	FOXO1	Breast Neoplasms	19574223	Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells
161	hsa-mir-96	FOXO1	Breast Neoplasms	19574223	Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells
162	hsa-mir-331	ERBB2	Prostatic Neoplasms	19584056	miR-311-3p regulate ERBB-2 expression and androgen receptor signaling in prostate cancer
163	hsa-mir-27a	ERBB2	Prostatic Neoplasms	19584056	decreased in prostate cancer; Regulates ERBB-2 Expression; blocked downstream phosphatidylinositol 3-kinase/AKT signaling, reducing activity of an androgen-stimulated prostate-specific antigen promoter and blocking prostate-specific antigen expression
164	hsa-mir-200b	BMI1	Breast Neoplasms	19665978	downregulated, modulate Expression of BMI1, suppressed tumor formation of normal stem cell
165	hsa-mir-200c	LRP1	Neoplasms	19665999	inhibits through down-regulating LRP1
166	hsa-mir-205	JAK2	Hodgkin Disease	19666866	Regulates JAK2, prognostic impact
167	hsa-mir-98	FUS1	Lung Neoplasms	19671678	regulate  tumor suppressor gene FUS1
168	hsa-mir-93	FUS1	Lung Neoplasms	19671678	regulate  tumor suppressor gene FUS1
169	hsa-mir-197	FUS1	Lung Neoplasms	19671678	regulate  tumor suppressor gene FUS1
170	hsa-mir-17	BCL2	Glioblastoma	19676043	inhibite Bcl-2 and Mcl-1, induce apoptosis
171	hsa-mir-18a	MCL1	Glioblastoma	19676043	inhibite Bcl-2 and Mcl-1, induce apoptosis
172	hsa-mir-19a	MCL1	Glioblastoma	19676043	inhibite Bcl-2 and Mcl-1, induce apoptosis
173	hsa-mir-17	MCL1	Glioblastoma	19676043	inhibite Bcl-2 and Mcl-1, induce apoptosis
174	hsa-mir-18a	BCL2	Glioblastoma	19676043	inhibite Bcl-2 and Mcl-1, induce apoptosis
175	hsa-mir-19a	BCL2	Glioblastoma	19676043	inhibite Bcl-2 and Mcl-1, induce apoptosis
176	hsa-mir-155	KGF	Fibroblasts	19701459	upregulates and target KGF 3'-UTR
177	hsa-mir-206	MET	Rhabdomyosarcoma	19710019	inhibits rhabdomyosarcoma through downregulating c-Met
178	hsa-mir-206	MET	Rhabdomyosarcoma	19710019	MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development
179	hsa-mir-1-1	MET	Rhabdomyosarcoma	19710019	inhibits rhabdomyosarcoma through downregulating c-Met
180	hsa-mir-1-2	MET	Rhabdomyosarcoma	19710019	inhibits rhabdomyosarcoma through downregulating c-Met
181	hsa-mir-15a	BCL2	Arthritis	19714650	induction of apoptosis in the synovium of mice,suppresses apoptosis through inhibition of Bcl-2
182	hsa-mir-15a	BCL2	Arthritis, Psoriatic	19714650	suppresses apoptosis through inhibition of Bcl-2
183	hsa-mir-133a-1	KLF15	Myocytes, Cardiac	19720047	MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes
184	hsa-mir-133b	KLF15	Myocytes, Cardiac	19720047	MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes
185	hsa-mir-133a-2	KLF15	Myocytes, Cardiac	19720047	MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes
186	hsa-mir-206	Notch3	Neoplasms	19723635	inhibits Notch3
187	hsa-mir-125b-1	BMPR1B	Breast Neoplasms	19738052	hsa-miR-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis
188	hsa-mir-125b-2	BMPR1B	Breast Neoplasms	19738052	hsa-miR-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis
189	hsa-let-7a-3	KRAS	Carcinoma	20033209	let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
190	hsa-let-7a-2	KRAS	Carcinoma	20033209	let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
191	hsa-let-7a-1	KRAS	Carcinoma	20033209	let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
192	hsa-let-7a-3	MYC	Carcinoma	20033209	let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
193	hsa-let-7a-2	MYC	Carcinoma	20033209	let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
194	hsa-let-7a-1	MYC	Carcinoma	20033209	let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
195	hsa-mir-491	BCL2L1	Colorectal Neoplasms	20039318	miR-491:Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells
196	hsa-mir-34a	BCL2	Neoplasms	20049626	miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
197	hsa-mir-34a	E2F1	Neoplasms	20049626	miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
198	hsa-mir-34a	E2F3	Neoplasms	20049626	miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
199	hsa-mir-34a	RB1	Neoplasms	20049626	miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
200	hsa-mir-34a	P53	Neoplasms	20049626	miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
201	hsa-mir-34c	BCL2	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
202	hsa-mir-34c	E2F1	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
203	hsa-mir-34c	E2F3	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
204	hsa-mir-34c	RB1	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
205	hsa-mir-34c	P53	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
206	hsa-mir-125a	BCL2	Neoplasms	20049626	miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
207	hsa-mir-125a	E2F1	Neoplasms	20049626	miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
208	hsa-mir-125a	E2F3	Neoplasms	20049626	miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
209	hsa-mir-125a	RB1	Neoplasms	20049626	miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
210	hsa-mir-125a	P53	Neoplasms	20049626	miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
211	hsa-mir-34b	BCL2	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
212	hsa-mir-34b	E2F1	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
213	hsa-mir-34b	E2F3	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
214	hsa-mir-34b	RB1	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
215	hsa-mir-34b	P53	Neoplasms	20049626	miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
216	hsa-mir-150	BCL2	Neoplasms	20049626	miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
217	hsa-mir-150	E2F1	Neoplasms	20049626	miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
218	hsa-mir-150	E2F3	Neoplasms	20049626	miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
219	hsa-mir-150	RB1	Neoplasms	20049626	miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
220	hsa-mir-150	P53	Neoplasms	20049626	miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
221	hsa-mir-106a	BCL2	Neoplasms	20049626	miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
222	hsa-mir-106a	E2F1	Neoplasms	20049626	miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
223	hsa-mir-106a	E2F3	Neoplasms	20049626	miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
224	hsa-mir-106a	RB1	Neoplasms	20049626	miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
225	hsa-mir-106a	P53	Neoplasms	20049626	miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
226	hsa-mir-16-2	BCL2	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
227	hsa-mir-16-2	E2F1	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
228	hsa-mir-16-2	E2F3	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
229	hsa-mir-16-2	RB1	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
230	hsa-mir-16-2	P53	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
231	hsa-mir-16-1	BCL2	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
232	hsa-mir-16-1	E2F1	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
233	hsa-mir-16-1	E2F3	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
234	hsa-mir-16-1	RB1	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
235	hsa-mir-16-1	P53	Neoplasms	20049626	miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
236	hsa-mir-205	MED1	Trophoblasts	20065103	miR-205:MiR-205 silences MED1 in hypoxic primary human trophoblasts; a set of seven miRNAs (miR-93, miR-205, miR-224, miR-335, miR-424, miR-451, and miR-491) that are differentially regulated in primary trophoblasts
237	hsa-mir-19a	ESR	Neuroblastoma	20080637	miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1)
238	hsa-mir-18a	ESR	Neuroblastoma	20080637	miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1)
239	hsa-mir-9-2	NFKB1	Stomach Neoplasms	20102618	miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth
240	hsa-mir-9-3	NFKB1	Stomach Neoplasms	20102618	miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth
241	hsa-mir-9-1	NFKB1	Stomach Neoplasms	20102618	miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth
242	hsa-mir-373	RECK	Neoplasms	20154725	miR-373:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
243	hsa-mir-21	RECK	Neoplasms	20154725	miR-21:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
244	hsa-mir-15b	RECK	Neoplasms	20154725	miR-15b:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
245	hsa-mir-16-2	RECK	Neoplasms	20154725	miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
246	hsa-mir-16-1	RECK	Neoplasms	20154725	miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
247	hsa-mir-372	RECK	Neoplasms	20154725	miR-372:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
248	hsa-mir-433	HDAC6	Chondrodysplasia Punctata	20181727	miR-433:A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia
249	hsa-mir-29a	NAV3	Alzheimer Disease	20202123	miR-29a decreased in Alzheimer disease brains targets neuron navigator-3
250	hsa-mir-21	PTEN	Lung Neoplasms	20223231	MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC)
251	hsa-mir-20b	HIF1A	Breast Neoplasms	20232316	miR-20b modulates VEGF expression by targeting HIF-1alpha and STAT3 in MCF-7 breast cancer cells
252	hsa-mir-20b	STAT3	Breast Neoplasms	20232316	miR-20b:miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells
253	hsa-mir-218-2	ROBO1	Stomach Neoplasms	20300657	MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.
254	hsa-mir-218-1	ROBO1	Stomach Neoplasms	20300657	MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.
255	hsa-mir-193b	CCND1	Melanoma	20304954	MicroRNA-193b Represses Cell Proliferationand Regulates Cyclin D1 in Melanoma
256	hsa-let-7g	COL1A2	Carcinoma, Hepatocellular	20338660	Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma.
257	hsa-mir-21	TIMP3	Breast Neoplasms	20346171	our data suggests that miR-21 could promote invasion in breast cancer cells via its regulation of TIMP3
258	hsa-let-7g	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7g:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
259	hsa-let-7a-1	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
260	hsa-let-7d	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7d:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
261	hsa-let-7f-2	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
262	hsa-let-7f-1	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
263	hsa-let-7e	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7e:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
264	hsa-let-7a-2	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
265	hsa-let-7c	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7c:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
266	hsa-let-7a-3	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
267	hsa-let-7i	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7i:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
268	hsa-let-7b	BCL2L1	Carcinoma, Hepatocellular	20347499	hsa-let-7b:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
269	hsa-let-7a-3	BCL2L1	Carcinoma, Hepatocellular	20347499	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
270	hsa-mir-34a	Notch1	Carcinoma	20351093	miR-34a:MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells
271	hsa-mir-34a	JAG1	Carcinoma	20351093	miR-34a:MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells
272	hsa-mir-155	SOCS1	Breast Neoplasms	20354188	MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene
273	hsa-mir-155	FOXO3a	Breast Neoplasms	20371610	MicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer
274	hsa-mir-155	FOXO3a	Breast Neoplasms	20371610	miR-155:miR-155 is a critical therapeutic target in breast cancer; MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer
275	hsa-mir-512-2	C-FLIP	Carcinoma, Hepatocellular	20372864	miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells
276	hsa-mir-512-1	C-FLIP	Carcinoma, Hepatocellular	20372864	miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells
277	hsa-mir-219-1	ID3	Child Development Disorders, Pervasive	20374639	Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
278	hsa-mir-219-1	PLK2	Child Development Disorders, Pervasive	20374639	Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
279	hsa-mir-219-2	ID3	Child Development Disorders, Pervasive	20374639	Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
280	hsa-mir-219-2	PLK2	Child Development Disorders, Pervasive	20374639	Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
281	hsa-mir-29b	ID3	Child Development Disorders, Pervasive	20374639	Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
282	hsa-mir-29b	PLK2	Child Development Disorders, Pervasive	20374639	Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
283	hsa-mir-148a	MSK1	Prostatic Neoplasms	20406806	miR-148a:MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression
284	hsa-mir-19a	p21	Leukemia, Myeloid, Acute	20406979	miR-19a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
285	hsa-mir-18a	p21	Leukemia, Myeloid, Acute	20406979	miR-18a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
286	hsa-mir-92a-2	p21	Leukemia, Myeloid, Acute	20406979	miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
287	hsa-mir-92a-1	p21	Leukemia, Myeloid, Acute	20406979	miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
288	hsa-mir-17	p21	Leukemia, Myeloid, Acute	20406979	miR-17:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
289	hsa-mir-19b-2	p21	Leukemia, Myeloid, Acute	20406979	miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
290	hsa-mir-19a	p21	Leukemia	20406979	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
291	hsa-mir-19b-1	p21	Leukemia, Myeloid, Acute	20406979	miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
292	hsa-mir-19b-2	p21	Leukemia	20406979	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
293	hsa-mir-20a	p21	Leukemia	20406979	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
294	hsa-mir-151a	MPL	Neoplasms	20445018	miR-151:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity
295	hsa-mir-708	MPL	Neoplasms	20445018	miR-708:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity
296	hsa-mir-28	MPL	Neoplasms	20445018	miR-28:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity
297	hsa-mir-155	CYR61	Pre-Eclampsia	20452491	miR-155:MicroRNA-155 contributes to preeclampsia by down-regulating CYR61
298	hsa-mir-20a	APP	Ovarian Neoplasms	20458444	miR-20a:miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells
299	hsa-mir-25	FXR1P	Muscular Dystrophy, Facioscapulohumeral	20519410	miR-25:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
300	hsa-mir-32	FXR1P	Muscular Dystrophy, Facioscapulohumeral	20519410	miR-32:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
301	hsa-mir-92a-1	FXR1P	Muscular Dystrophy, Facioscapulohumeral	20519410	miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
302	hsa-mir-92a-2	FXR1P	Muscular Dystrophy, Facioscapulohumeral	20519410	miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
303	hsa-mir-363	FXR1P	Muscular Dystrophy, Facioscapulohumeral	20519410	miR-363:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
304	hsa-mir-367	FXR1P	Muscular Dystrophy, Facioscapulohumeral	20519410	miR-367:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
305	hsa-mir-661	PVRL1	Breast Neoplasms	20543867	miR-661:miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers
306	hsa-mir-661	STARD10	Breast Neoplasms	20543867	miR-661:miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers
307	hsa-mir-375	JAK2	Stomach Neoplasms	20548334	MiR-375:MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2
308	hsa-mir-22	MYCBP	Neoplasms	20562918	miR-22:miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities.
309	hsa-mir-185	SIX1	Neoplasms	20603620	miRNA-185:MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers
310	hsa-mir-96	KRAS	Pancreatic Neoplasms	20610624	miRNA-96:miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer
311	hsa-mir-149	AKT1	Neoplasms	20623644	miR-149:miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells
312	hsa-mir-149	E2F1	Neoplasms	20623644	miR-149:miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells
313	hsa-mir-27a	HIPK2	Ovarian Neoplasms	20624637	MiR-27a:MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells
314	hsa-mir-137	MITF	Melanoma	20644734	miR-137:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells.
315	hsa-mir-148a	MITF	Melanoma	20644734	miR-148:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells.
316	hsa-mir-24-1	DND1	Carcinoma, Squamous Cell	20816961	miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma
317	hsa-mir-24-2	DND1	Carcinoma, Squamous Cell	20816961	miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma
318	hsa-mir-128-2	NTRK3	Neuroblastoma	21143953	Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells.
319	hsa-mir-128-1	NTRK3	Neuroblastoma	21143953	Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells.
320	hsa-mir-21	THRB	Thyroid Neoplasms	21159845	Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a.
321	hsa-mir-146a	THRB	Thyroid Neoplasms	21159845	Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a.
322	hsa-mir-569	SPI1	Lupus Erythematosus, Systemic	21162035	Association of a functional polymorphism in the 3' untranslated region of SPI1 with systemic lupus erythematosus.
323	hsa-mir-107	COFILIN	Alzheimer Disease	21179570	microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD
324	hsa-mir-103a-2	COFILIN	Alzheimer Disease	21179570	microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD
325	hsa-mir-103a-1	COFILIN	Alzheimer Disease	21179570	microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD
326	hsa-mir-185	RhoA	Colorectal Neoplasms	21186079	miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells.miR-185 is a negative regulator of RhoA and Cdc42 and their cellular activities, and could inhibit proliferation and invasion of colorectal cancer
327	hsa-mir-185	CDC42	Colorectal Neoplasms	21186079	miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells.miR-185 is a negative regulator of RhoA and Cdc42 and their cellular activities, and could inhibit proliferation and invasion of colorectal cancer
328	hsa-mir-21	PTEN	Leukemia	21187093	Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line.
329	hsa-mir-26a-1	EZH2	Nasopharyngeal Neoplasms	21199804	MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2
330	hsa-mir-26a-2	EZH2	Nasopharyngeal Neoplasms	21199804	MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2
331	hsa-mir-203	BCL2L2	Urinary Bladder Neoplasms	21205209	microRNA-203 suppresses bladder cancer development by repressing bcl-w expression.
332	hsa-mir-195	p53	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
333	hsa-mir-16-2	p53	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
334	hsa-mir-16-1	p53	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
335	hsa-mir-15b	p53	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
336	hsa-mir-15a	p53	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
337	hsa-mir-34c	p53	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
338	hsa-mir-34b	p53	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
339	hsa-mir-31	DMD	Muscular Dystrophy, Duchenne	21212803	miR-31 represses dystrophin expression by targeting its 3' untranslated region.
340	hsa-mir-214	PLXNB1	Uterine Cervical Neoplasms	21216304	Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa Cells.
341	hsa-mir-328	BCRP	Breast Neoplasms	21219875	Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
342	hsa-mir-520h	BCRP	Breast Neoplasms	21219875	Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
343	hsa-mir-519c	BCRP	Breast Neoplasms	21219875	Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
344	hsa-mir-616	TFPI2	Prostatic Neoplasms	21224345	microRNA-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor TFPI-2.
345	hsa-mir-376c	ACVR1C	Ovarian Neoplasms	21224400	MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
346	hsa-mir-200c	ZEB1	Breast Neoplasms	21224848	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
347	hsa-mir-200a	ZEB1	Pancreatic Neoplasms	21224848	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
348	hsa-mir-200c	ZEB1	Pancreatic Neoplasms	21224848	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
349	hsa-mir-200b	ZEB1	Breast Neoplasms	21224848	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
350	hsa-mir-200a	ZEB1	Breast Neoplasms	21224848	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
351	hsa-mir-200b	ZEB1	Pancreatic Neoplasms	21224848	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
352	hsa-mir-9-2	CDX2	Stomach Neoplasms	21225631	MiR-9 down-regulates CDX2 expression in gastric cancer cells.
353	hsa-mir-9-3	CDX2	Stomach Neoplasms	21225631	MiR-9 down-regulates CDX2 expression in gastric cancer cells.
354	hsa-mir-9-3	CDX2	Stomach Neoplasms	21225631	MiR-9 downregulates CDX2 expression in gastric cancer cells.
355	hsa-mir-9-1	CDX2	Stomach Neoplasms	21225631	MiR-9 down-regulates CDX2 expression in gastric cancer cells.
356	hsa-mir-9-1	CDX2	Stomach Neoplasms	21225631	MiR-9 downregulates CDX2 expression in gastric cancer cells.
357	hsa-mir-9-2	CDX2	Stomach Neoplasms	21225631	MiR-9 downregulates CDX2 expression in gastric cancer cells.
358	hsa-mir-340	MET	Breast Neoplasms	21225860	miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met
359	hsa-mir-885	CDK2	Neuroblastoma	21233845	MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival.
360	hsa-mir-885	MCM5	Neuroblastoma	21233845	MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival.
361	hsa-mir-155	AGTR1	Pre-Eclampsia	21234519	microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women.
362	hsa-mir-34a	CD44	Prostatic Neoplasms	21240262	The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
363	hsa-mir-20a	BNIP2	Colorectal Neoplasms	21242194	miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
364	hsa-mir-126	VEGFA	Breast Neoplasms	21249429	Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2.
365	hsa-mir-126	PIK3R2	Breast Neoplasms	21249429	Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2.
366	hsa-mir-145	FSCN1	Prostatic Neoplasms	21258769	Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1.
367	hsa-mir-26b	EphA2	Glioma	21264258	This study demonstrated that miR-26b may act as a tumor suppressor in glioma and it directly regulates EphA2 expression. EphA2 is a direct target of miR-26b, and the down-regulation of EphA2 mediated by miR-26b is dependent on the binding of miR-26b to a
368	hsa-mir-107	CDK6	Gastrointestinal Neoplasms	21264532	miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.
369	hsa-mir-19a	TNF	Esophageal Neoplasms	21271217	TNF-alpha is a novel target of miR-19a.
370	hsa-mir-381	MIT	Mastocytosis, Systemic	21273305	We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR.
371	hsa-mir-539	MIT	Mastocytosis, Systemic	21273305	We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR.
372	hsa-mir-221	CDKN1C	Colorectal Neoplasms	21278784	MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma.
373	hsa-mir-21	Spry2	Glioma	21278789	Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas.
374	hsa-mir-145	EGFR	Lung Neoplasms	21289483	MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1.
375	hsa-mir-145	NUDT1	Lung Neoplasms	21289483	MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1.
376	hsa-mir-141	YAP1	Esophageal Neoplasms	21289630	MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.
377	hsa-mir-203	p63	Esophageal Neoplasms	21299870	MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma.
378	hsa-mir-203	p63	Carcinoma, Squamous Cell	21299870	MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma.
379	hsa-mir-1-2	TAGLN2	Urinary Bladder Neoplasms	21304530	The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
380	hsa-mir-133a-1	TAGLN2	Urinary Bladder Neoplasms	21304530	The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
381	hsa-mir-133a-2	TAGLN2	Urinary Bladder Neoplasms	21304530	The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
382	hsa-mir-1-1	TAGLN2	Urinary Bladder Neoplasms	21304530	The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
383	hsa-mir-126	SOX2	Gastrointestinal Neoplasms	21304604	miR-126 is a novel miRNA that targets SOX2, and PLAC1 may be a novel downstream target gene of SOX2 in gastric cancer cells. These findings suggest that aberrant over-expression of miR-126 and consequent SOX2 down-regulation may contribute to gastric carc
384	hsa-mir-125b-1	MUC1	Prostatic Neoplasms	21308711	miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels.
385	hsa-mir-125b-2	MUC1	Prostatic Neoplasms	21308711	miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels.
386	hsa-mir-222	ETS1	Inflammation	21310411	HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and
387	hsa-mir-221	ETS1	Inflammation	21310411	HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and
388	hsa-mir-155	AT1R	Inflammation	21310411	HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and
389	hsa-mir-155	ETS1	Inflammation	21310411	HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and
390	hsa-mir-21	ANP32A	Prostatic Neoplasms	21317927	MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4
391	hsa-mir-21	SMARCA4	Prostatic Neoplasms	21317927	MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4
392	hsa-mir-199a-2	AXL	Carcinoma, Non-Small-Cell Lung	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
393	hsa-mir-199a-2	AXL	Breast Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
394	hsa-mir-199a-1	AXL	Carcinoma, Non-Small-Cell Lung	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
395	hsa-mir-199a-1	AXL	Breast Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
396	hsa-mir-199a-2	AXL	Colorectal Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
397	hsa-mir-34a	AXL	Colorectal Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
398	hsa-mir-199b	AXL	Breast Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
399	hsa-mir-199a-1	AXL	Colorectal Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
400	hsa-mir-34a	AXL	Breast Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
401	hsa-mir-199b	AXL	Carcinoma, Non-Small-Cell Lung	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
402	hsa-mir-199b	AXL	Colorectal Neoplasms	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
403	hsa-mir-34a	AXL	Carcinoma, Non-Small-Cell Lung	21317930	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
404	hsa-mir-124-1	IQGAP1	Breast Neoplasms	21318219	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.
405	hsa-mir-124-2	IQGAP1	Breast Neoplasms	21318219	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.
406	hsa-mir-124-3	IQGAP1	Breast Neoplasms	21318219	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.
407	hsa-mir-34c	MYC	Colorectal Neoplasms	21329882	MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it
408	hsa-mir-34b	MYC	Colorectal Neoplasms	21329882	MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it
409	hsa-let-7a-1	RAB40C	Gastrointestinal Neoplasms	21349817	let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas
410	hsa-let-7a-2	RAB40C	Gastrointestinal Neoplasms	21349817	let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas
411	hsa-let-7a-3	RAB40C	Gastrointestinal Neoplasms	21349817	let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas
412	hsa-mir-451a	RAB14	Carcinoma, Non-Small-Cell Lung	21358675	MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14).
413	hsa-mir-16-1	ZYX	Laryngeal Neoplasms	21360639	MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2.
414	hsa-mir-16-2	ZYX	Laryngeal Neoplasms	21360639	MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2.
415	hsa-mir-145	OCT4	Adenocarcinoma	21365617	Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells.
416	hsa-mir-34a	E2F1	Leukemia	21367750	miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells.
417	hsa-mir-34a	MYB	Leukemia	21367750	miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells.
418	hsa-mir-1-1	TAGLN2	Head and Neck Neoplasms	21378409	miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
419	hsa-mir-1-2	TAGLN2	Carcinoma, Squamous Cell	21378409	miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
420	hsa-mir-1-2	TAGLN2	Head and Neck Neoplasms	21378409	miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
421	hsa-mir-1-1	TAGLN2	Carcinoma, Squamous Cell	21378409	miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
422	hsa-mir-9-1	JAK	Glioblastoma	21385897	miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3.
423	hsa-mir-9-2	JAK	Glioblastoma	21385897	miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3.
424	hsa-mir-9-3	JAK	Glioblastoma	21385897	miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3.
425	hsa-mir-204	FOXC1	Endometrial Neoplasms	21400511	Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1.
426	hsa-mir-125b-1	FGFR2	Psoriasis	21412257	MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2.
427	hsa-mir-125b-2	FGFR2	Psoriasis	21412257	MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2.
428	hsa-mir-204	EZR	Stomach Neoplasms	21416062	MiR-204, which was predicted to target ezrin, was downregulated in gastric cancer cells and gastric carcinomas. MiR-204 inhibited ezrin expression, Ras activation, cell growth and cell migration
429	hsa-mir-204	PDEF	Prostatic Neoplasms	21446014	PDEF expression is regulated via a functional microRNA-204 (miR-204) binding site within the 3'UTR. Furthermore, we demonstrate the biologic significance of miR-204 expression and that miR-204 is over-expressed in human prostate cancer specimens.
430	hsa-mir-148a	BCL2	Colorectal Neoplasms	21455217	MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer.
431	hsa-mir-214	TFAP2C	Melanoma	21468029	miR-214 is highly expressed in human melanomas and contributes to melanoma tumour progression through suppression of TFAP2C
432	hsa-mir-145	OCT4	Lung Neoplasms	21479367	microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4.
433	hsa-mir-373	PPP6C	Carcinoma, Hepatocellular	21481188	miR-373 can regulate cell cycle progression by targeting PPP6C transcripts and promotes the growth activity of hepatocellular carcinoma cells in vitro. This miRNA functions as an oncogene in hepatocellular carcinoma.
434	hsa-mir-142	RAC1	Carcinoma, Hepatocellular	21482222	MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells.
435	hsa-mir-221	DVL2	Prostatic Neoplasms	21487968	MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2.
436	hsa-mir-223	MYC	Carcinoma, Hepatocellular	21492514	microRNA-223 and its target gene oncogene c-myc have roles in hepatocellular carcinoma pathogenesis.
437	hsa-mir-145	OCT4	Lung Neoplasms	21496429	miR-145 Inhibits Lung Adenocarcinoma Stem Cells Proliferation by Targeting OCT4  Gene.
438	hsa-mir-18a	CTGF	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
439	hsa-mir-18b	CTGF	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
440	hsa-mir-19b-1	CTGF	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
441	hsa-mir-19b-2	CTGF	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
442	hsa-mir-19a	CTGF	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
443	hsa-mir-18a	TSP1	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
444	hsa-mir-18b	TSP1	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
445	hsa-mir-19b-1	TSP1	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
446	hsa-mir-19b-2	TSP1	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
447	hsa-mir-19a	TSP1	Heart Failure	21501375	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
448	hsa-mir-26b	SLC7A11	Breast Neoplasms	21510944	MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11.
449	hsa-mir-519d	MKi67	Carcinoma, Hepatocellular	21524841	MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703.
450	hsa-mir-622	ING1	Stomach Neoplasms	21528065	Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene.
451	hsa-mir-200a	ZEB2	Ovarian Neoplasms	21529905	MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2.
452	hsa-let-7f-1	MYH9	Stomach Neoplasms	21533124	MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer.
453	hsa-let-7f-2	MYH9	Stomach Neoplasms	21533124	MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer.
454	hsa-let-7d	PBX3	Prostatic Neoplasms	21548940	PBX3 is up-regulated in prostate cancer and post- transcriptionally regulated by androgen through Let-7d.
455	hsa-mir-125b-1	BMPR1B	Prostatic Neoplasms	21556765	rs1434536 in the 3'UTR of BMPR1B gene affects the binding ability of miR-125b to BMPR1B mRNA and contributes to the genetic hspredisposition to localized prostate cancer and patients aged >70years.
456	hsa-mir-125b-2	BMPR1B	Prostatic Neoplasms	21556765	rs1434536 in the 3'UTR of BMPR1B gene affects the binding ability of miR-125b to BMPR1B mRNA and contributes to the genetic hspredisposition to localized prostate cancer and patients aged >70years.
457	hsa-mir-637	ATP6V0A1	Hypertension	21558123	A common genetic variant (rs938671) in the 3'-UTR of Vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA (hsa-miR-637) motif to alter Chromogranin A (CHGA) processing and hypertension risk.
458	hsa-mir-342	DNMT1	Colorectal Neoplasms	21565830	MicroRNA-342 Inhibits Colorectal Cancer Cell Proliferation and Invasion by Directly Targeting DNA Methyltransferase 1.
459	hsa-mir-1302-2	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
460	hsa-mir-1302-7	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
461	hsa-mir-1302-1	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
462	hsa-mir-1302-8	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
463	hsa-mir-1302-3	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
464	hsa-mir-1302-4	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
465	hsa-mir-1302-5	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
466	hsa-mir-1302-6	CGA	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
467	hsa-mir-1302-2	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
468	hsa-mir-1302-7	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
469	hsa-mir-1302-1	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
470	hsa-mir-1302-8	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
471	hsa-mir-1302-3	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
472	hsa-mir-1302-4	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
473	hsa-mir-1302-5	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
474	hsa-mir-1302-6	CPEB1	Infertility, Male	21601192	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 an
475	hsa-let-7a-1	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
476	hsa-let-7e	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
477	hsa-let-7a-2	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
478	hsa-let-7d	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
479	hsa-let-7f-1	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
480	hsa-let-7b	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
481	hsa-let-7c	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
482	hsa-let-7g	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
483	hsa-let-7i	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
484	hsa-let-7a-3	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
485	hsa-let-7f-2	IL13	Inflammation	21616524	Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
486	hsa-mir-223	EPB41L3	Stomach Neoplasms	21628394	miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3.
487	hsa-mir-100	RBSP3	Leukemia, Myeloid, Acute	21643017	MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia.
488	hsa-mir-372	CDK2	Uterine Cervical Neoplasms	21646351	MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis.
489	hsa-mir-372	CCNA1	Uterine Cervical Neoplasms	21646351	MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis.
490	hsa-mir-338	SMO	Carcinoma, Hepatocellular	21671467	miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened.
491	hsa-mir-192	ERCC3	Carcinoma, Hepatocellular	21672525	MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells.
492	hsa-mir-192	ERCC4	Carcinoma, Hepatocellular	21672525	MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells.
493	hsa-mir-124-2	ROCK2	Carcinoma, Hepatocellular	21672940	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
494	hsa-mir-124-1	ROCK2	Carcinoma, Hepatocellular	21672940	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
495	hsa-mir-124-3	ROCK2	Carcinoma, Hepatocellular	21672940	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
496	hsa-mir-124-2	EZH2	Carcinoma, Hepatocellular	21672940	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
497	hsa-mir-124-1	EZH2	Carcinoma, Hepatocellular	21672940	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
498	hsa-mir-124-3	EZH2	Carcinoma, Hepatocellular	21672940	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
499	hsa-mir-340	MET	Breast Neoplasms	21692045	miR-340 inhibites breast cancer cell migration and invasion through targeting of oncoprotein c-Met.
500	hsa-mir-148a	CDC25B	Pancreatic Neoplasms	21709669	MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.
501	hsa-mir-488	AR	Prostatic Neoplasms	21710544	miR 488* inhibits androgen receptor expression in prostate carcinoma cells.
502	hsa-mir-302d	CXCR4	Glioblastoma	21720384	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
503	hsa-mir-302a	CXCR4	Glioblastoma	21720384	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
504	hsa-mir-302b	CXCR4	Glioblastoma	21720384	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
505	hsa-mir-302c	CXCR4	Glioblastoma	21720384	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
506	hsa-mir-367	CXCR4	Glioblastoma	21720384	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
507	hsa-mir-187	DAB2	Ovarian Neoplasms	21725366	microRNA-187 Regulates of ovarian cancer progression through targeting Disabled homolog-2.
508	hsa-mir-15b	BMI1	Tongue Neoplasms	21725369	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.
509	hsa-mir-200b	BMI1	Tongue Neoplasms	21725369	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.
510	hsa-mir-221	SLC25A3	Glioblastoma	21743492	miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu.
511	hsa-mir-222	SLC25A3	Glioblastoma	21743492	miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu.
512	hsa-mir-7-1	BCL2	Carcinoma, Non-Small-Cell Lung	21750649	MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2.
513	hsa-mir-7-3	BCL2	Carcinoma, Non-Small-Cell Lung	21750649	MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2.
514	hsa-mir-7-2	BCL2	Carcinoma, Non-Small-Cell Lung	21750649	MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2.
515	hsa-mir-1-2	CCND2	Thyroid Neoplasms	21752897	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
516	hsa-mir-1-1	CCND2	Thyroid Neoplasms	21752897	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
517	hsa-mir-1-2	CXCR4	Thyroid Neoplasms	21752897	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
518	hsa-mir-1-1	CXCR4	Thyroid Neoplasms	21752897	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
519	hsa-mir-1-2	CXCL12	Thyroid Neoplasms	21752897	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
520	hsa-mir-1-1	CXCL12	Thyroid Neoplasms	21752897	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
521	hsa-mir-375	MTDH	Carcinoma, Squamous Cell	21753766	Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC).
522	hsa-mir-29c	TNFAIP3	Carcinoma, Hepatocellular	21763284	miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.
523	hsa-mir-133a-1	COL1A1	Hypertension	21769867	MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension.
524	hsa-mir-133a-2	COL1A1	Hypertension	21769867	MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension.
525	hsa-mir-143	Ptgs2	Urinary Bladder Neoplasms	21790228	Expression of miR-143 Reduces Growth and Migration of Human Bladder Carcinoma Cells by Targeting Cyclooxygenase-2.
526	hsa-mir-29b-1	MMP2	Carcinoma, Hepatocellular	21793034	MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression.
527	hsa-mir-29b-2	MMP2	Carcinoma, Hepatocellular	21793034	MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression.
528	hsa-mir-218-2	RICTOR	Carcinoma, Squamous Cell	21795477	The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.
529	hsa-mir-218-1	RICTOR	Carcinoma, Squamous Cell	21795477	The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.
530	hsa-mir-19a	DKK3	Neuroblastoma	21796614	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
531	hsa-mir-19b-1	DKK3	Neuroblastoma	21796614	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
532	hsa-mir-92a-1	DKK3	Neuroblastoma	21796614	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
533	hsa-mir-17	DKK3	Neuroblastoma	21796614	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
534	hsa-mir-20a	DKK3	Neuroblastoma	21796614	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
535	hsa-mir-18a	DKK3	Neuroblastoma	21796614	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
536	hsa-mir-210	ISCU	Pre-Eclampsia	21801864	miR-210 Targets Iron-Sulfur Cluster Scaffold Homologue
537	hsa-mir-199a-2	CAV2	Carcinoma, Hepatocellular	21807947	MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
538	hsa-mir-199a-1	CAV2	Urinary Bladder Neoplasms	21807947	MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
539	hsa-mir-199a-1	CAV2	Carcinoma, Hepatocellular	21807947	MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
540	hsa-mir-199a-2	CAV2	Urinary Bladder Neoplasms	21807947	MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
541	hsa-mir-367	RYR3	Breast Neoplasms	21810988	Functional SNP (rs1044129, is present in binding region) in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification.
542	hsa-mir-375	IGF1R	Carcinoma, Squamous Cell	21813472	MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor.
543	hsa-mir-34a	AXL	Breast Neoplasms	21814748	Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
544	hsa-mir-106b	RB	Laryngeal Neoplasms	21819631	MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma.
545	hsa-mir-335	BCL2L2	Stomach Neoplasms	21822301	MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1.
546	hsa-mir-146b	MMP16	Pancreatic Neoplasms	21823013	miR-146b-5p has inhibitory effects of  on cell migration and invasion of pancreatic cancer by targeting MMP16.
547	hsa-mir-125b-2	BCL2	Ovarian Neoplasms	21823019	miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.
548	hsa-mir-125b-1	BCL2	Ovarian Neoplasms	21823019	miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.
549	hsa-mir-21	Spry1	Prostatic Neoplasms	21826097	Spry1 is a target for miR-21-mediated gene silencing.
550	hsa-mir-451a	Ywhaz	Diabetic Nephropathies	21827757	MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early Diabetic Nephropathies.
551	hsa-mir-144	IRS1	Diabetes Mellitus, Type 2	21829658	MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus.
552	hsa-mir-194-1	BMI1	Endometrial Neoplasms	21851624	MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
553	hsa-mir-194-2	BMI1	Endometrial Neoplasms	21851624	MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
554	hsa-mir-375	YAP1	Lung Neoplasms	21856745	miR-375 is activated by ASH1 and inhibits YAP1 in a lineage dependent manner in lung cancer.
555	hsa-mir-9-3	CAMTA1	Glioblastoma	21857646	CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells.
556	hsa-mir-9-2	CAMTA1	Glioblastoma	21857646	CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells.
557	hsa-mir-9-1	CAMTA1	Glioblastoma	21857646	CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells.
558	hsa-mir-221	TRPS1	Breast Neoplasms	21868360	miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer.
559	hsa-mir-222	TRPS1	Breast Neoplasms	21868360	miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer.
560	hsa-mir-21	RhoB	Colorectal Neoplasms	21872591	miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells.
561	hsa-mir-216b	KRAS	Nasopharyngeal Neoplasms	21878506	miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma.
562	hsa-mir-423	p21Cip1	Carcinoma, Hepatocellular	21890460	MicroRNA-423 Promotes Cell Growth and Regulates G1/S Transition by Targeting p21Cip1/Waf1 in Hepatocellular Carcinoma
563	hsa-mir-373	mTOR	Fibrosarcoma	21898400	miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-¦ÊB; and finally increasing the mRN
564	hsa-mir-373	SIRT1	Fibrosarcoma	21898400	miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-¦ÊB; and finally increasing the mRN
565	hsa-mir-520c	mTOR	Fibrosarcoma	21898400	miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-¦ÊB; and finally increasing the mRN
566	hsa-mir-520c	SIRT1	Fibrosarcoma	21898400	miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-¦ÊB; and finally increasing the mRN
567	hsa-mir-200c	ZEB1	Head and Neck Neoplasms	21899661	The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation.
568	hsa-mir-200c	ZEB1	Carcinoma, Squamous Cell	21899661	The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation.
569	hsa-mir-27b	ST14	Head and Neck Neoplasms	21899661	The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation.
570	hsa-mir-27b	ST14	Carcinoma, Squamous Cell	21899661	The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation.
571	hsa-mir-224	DIO1	Carcinoma, Renal Cell	21912701	MiR-224 Targets the 3'UTR of Type 1 5'-Iodothyronine Deiodinase Possibly Contributing to Tissue Hypothyroidism in Renal Cancer.
572	hsa-mir-145	p70S6K1	Colonic Neoplasms	21917858	The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis.
573	hsa-mir-145	p70S6K1	Ovarian Neoplasms	21917858	The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis.
574	hsa-mir-1-1	FN1	Carcinoma, Squamous Cell	21924268	miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
575	hsa-mir-1-1	FN1	Laryngeal Neoplasms	21924268	miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
576	hsa-mir-1-2	FN1	Carcinoma, Squamous Cell	21924268	miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
577	hsa-mir-1-2	FN1	Laryngeal Neoplasms	21924268	miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
578	hsa-mir-200a	Keap1	Breast Neoplasms	21926171	miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.
579	hsa-mir-23a	MAFbx	Atrophy	21926429	miR-23a suppresses the translation of both MAFbx/atrogin-1 and MuRF1 in a 3UTR-dependent manner. Ectopic expression of miR-23a is sufficient to protect muscles from atrophy in vitro and in vivo.
580	hsa-mir-23a	MuRF1	Atrophy	21926429	miR-23a suppresses the translation of both MAFbx/atrogin-1 and MuRF1 in a 3UTR-dependent manner. Ectopic expression of miR-23a is sufficient to protect muscles from atrophy in vitro and in vivo.
581	hsa-mir-499a	FOXO4	Colorectal Neoplasms	21934092	microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4.
582	hsa-mir-499a	PDCD4	Colorectal Neoplasms	21934092	microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4.
583	hsa-mir-195	BCL2L2	Carcinoma, Hepatocellular	21947305	miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.
584	hsa-mir-191	NDST1	Stomach Neoplasms	21947487	MicroRNA-191 targets N-deacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803.
585	hsa-mir-25	TNFRSF10A	Cholangiocarcinoma	21953056	miR-25 targets TRAIL death Receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.
586	hsa-mir-185	DNMT3A	Glioma	21962230	MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma.
587	hsa-mir-185	DNMT3B	Glioma	21962230	MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma.
588	hsa-mir-125b-1	TP53INP1	Endometrial Neoplasms	21970405	MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo.
589	hsa-mir-125b-2	TP53INP1	Endometrial Neoplasms	21970405	MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo.
590	hsa-mir-608	HIL6	Sarcoma, Kaposi	21984125	We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or
591	hsa-mir-1293	VIL6	Sarcoma, Kaposi	21984125	We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or
592	hsa-let-7c	MMP11	Colorectal Neoplasms	21984339	Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer.
593	hsa-let-7c	PBX3	Colorectal Neoplasms	21984339	Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer.
594	hsa-mir-200b	BCL2	Stomach Neoplasms	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
595	hsa-mir-200b	BCL2	Carcinoma, Non-Small-Cell Lung	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
596	hsa-mir-200c	BCL2	Stomach Neoplasms	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
597	hsa-mir-200c	BCL2	Carcinoma, Non-Small-Cell Lung	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
598	hsa-mir-429	BCL2	Stomach Neoplasms	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
599	hsa-mir-429	BCL2	Carcinoma, Non-Small-Cell Lung	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
600	hsa-mir-200b	XIAP	Stomach Neoplasms	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
601	hsa-mir-200b	XIAP	Carcinoma, Non-Small-Cell Lung	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
602	hsa-mir-200c	XIAP	Stomach Neoplasms	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
603	hsa-mir-200c	XIAP	Carcinoma, Non-Small-Cell Lung	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
604	hsa-mir-429	XIAP	Stomach Neoplasms	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
605	hsa-mir-429	XIAP	Carcinoma, Non-Small-Cell Lung	21993663	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
606	hsa-mir-148b	CCKBR	Colorectal Neoplasms	22020560	MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer.
607	hsa-mir-146a	SMAD4	Stomach Neoplasms	22020746	Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis.
608	hsa-mir-214	HTT	Huntington Disease	22048026	Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
609	hsa-mir-150	HTT	Huntington Disease	22048026	Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
610	hsa-mir-125b-2	HTT	Huntington Disease	22048026	Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
611	hsa-mir-125b-1	HTT	Huntington Disease	22048026	Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
612	hsa-mir-146a	HTT	Huntington Disease	22048026	Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
613	hsa-mir-375	AEG1	Carcinoma, Hepatocellular	22056881	MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.
614	hsa-mir-133a-2	PNP	Prostatic Neoplasms	22068816	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
615	hsa-mir-1-2	PNP	Prostatic Neoplasms	22068816	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
616	hsa-mir-1-1	PNP	Prostatic Neoplasms	22068816	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
617	hsa-mir-133a-1	PNP	Prostatic Neoplasms	22068816	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
618	hsa-mir-21	GRHL3	Carcinoma, Squamous Cell	22094257	Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis.
619	hsa-mir-21	CCL20	Colorectal Neoplasms	22099878	miR-21 functionally interacts with the 3'UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells.
620	hsa-mir-520e	NIK	Carcinoma, Hepatocellular	22105365	MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kB-inducing kinase (NIK).
621	hsa-mir-143	SERPINE1	Urinary Bladder Neoplasms	22108519	The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer.
622	hsa-mir-145	SERPINE1	Urinary Bladder Neoplasms	22108519	The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer.
623	hsa-mir-34b	CCND1	Breast Neoplasms	22113133	In this study, we identified one such estrogen down-regulated microRNA, miR-34b, as an onco-suppressor that targets cyclin D1 and JAG-1 (jagged 1) in a ER-positive/wild-type p53 breast cancer cell line (MCF-7) as well as in ovarian and endometrial cells,
624	hsa-mir-34b	CCND1	Breast Neoplasms	22113133	In this study, we identified one such estrogen down-regulated microRNA, miR-34b, as an onco-suppressor that targets cyclin D1 and JAG-1 (jagged 1) in a ER-positive/wild-type p53 breast cancer cell line (MCF-7) as well as in ovarian and endometrial cells,
625	hsa-mir-27b	JAG1	Neuroblastoma	22120719	MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells.
626	hsa-mir-1915	BCL2	Colorectal Neoplasms	22121083	miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.
627	hsa-mir-221	p57	Colonic Neoplasms	22126772	MicroRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKN1C/p57 expression.
628	hsa-mir-17	RND3	Colorectal Neoplasms	22132820	Up-regulated miR-17 promotes cell proliferation, tumor growth and cell cycle progression by targeting RND3 tumor suppressor gene in colorectal carcinoma.
629	hsa-mir-320a	NRP1	Colorectal Neoplasms	22134529	microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer.
630	hsa-mir-210	VMP1	Carcinoma, Hepatocellular	22144109	Hypoxia-inducible MicroRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma.
631	hsa-mir-200c	FHOD1	Breast Neoplasms	22144583	MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.
632	hsa-mir-200c	PPM1F	Breast Neoplasms	22144583	MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.
633	hsa-mir-23b	NOX4	Pain	22149086	MiR23b Ameliorates Neuropathic Pain in Spinal Cord by Silencing NOX4.
634	hsa-mir-1245a	BRCA2	Breast Neoplasms	22158906	Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair.
635	hsa-mir-1245b	BRCA2	Breast Neoplasms	22158906	Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair.
636	hsa-mir-34a	MYC	Carcinoma, Renal Cell	22159222	MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma.
637	hsa-mir-205	VEGFA	Glioblastoma	22159356	MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A.
638	hsa-mir-143	BCL2	Uterine Cervical Neoplasms	22160209	miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2.
639	hsa-mir-137	CSMD1	Schizophrenia	22182936	Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets.
640	hsa-mir-137	C10orf26	Schizophrenia	22182936	Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets.
641	hsa-mir-137	CACNA1C	Schizophrenia	22182936	Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets.
642	hsa-mir-137	TCF4	Schizophrenia	22182936	Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets.
643	hsa-mir-200c	CCNE2	Lymphoma	22183793	MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.
644	hsa-mir-200b	CCNE2	Lymphoma	22183793	MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.
645	hsa-mir-200a	CCNE2	Lymphoma	22183793	MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.
646	hsa-mir-570	CD274	Stomach Neoplasms	22190470	A guanine-to-cytosine mutation at the 3'-UTR of CD274 mRNA led to CD274 over-expression by disrupting the miR-570 binding. A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding.
647	hsa-mir-200b	TFAP2A	Endometrial Neoplasms	22194984	Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2alpha gene and negatively regulated the expression of endogenous AP-2alpha proteins. SNP rs1045385 A>C variation enhanced AP-2alpha.
648	hsa-mir-429	TFAP2A	Endometrial Neoplasms	22194984	Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2 alpha gene and negatively regulated the expression of endogenous AP-2 alpha proteins. SNP rs1045385 A>C variation enhanced AP-2 alpha expression.
649	hsa-mir-200c	TFAP2A	Endometrial Neoplasms	22194984	Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2 alpha gene and negatively regulated the expression of endogenous AP-2 alpha proteins. SNP rs1045385 A>C variation enhanced AP-2 alpha expression.
650	hsa-mir-181d	KRAS	Glioma	22207524	MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.
651	hsa-mir-181d	BCL2	Glioma	22207524	MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.
652	hsa-mir-34a	BIRC5	Laryngeal Neoplasms	22246523	MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin.
653	hsa-mir-124-1	HMGA1	Medulloblastoma	22249617	hsa-miR-124a targeted 3'UTR of HMGA1 and negatively modulated the expression in MB cells.
654	hsa-let-7i	RAS	Pancreatic Neoplasms	22261338	The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro.
655	hsa-mir-143	RAS	Pancreatic Neoplasms	22261338	The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro.
656	hsa-let-7f-2	IL23R	Crohn Disease	22262659	The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the varian
657	hsa-let-7e	IL23R	Crohn Disease	22262659	The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the varian
658	hsa-let-7f-1	IL23R	Crohn Disease	22262659	The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the varian
659	hsa-mir-195	GLUT3	Urinary Bladder Neoplasms	22265971	MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression.
660	hsa-mir-32	BTG2	Prostatic Neoplasms	22266859	Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
661	hsa-mir-21	PTEN	Stomach Neoplasms	22267008	microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN.
662	hsa-mir-30a	DTL	Colonic Neoplasms	22287560	MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.
663	hsa-mir-127	FCGR1A	Inflammation	22287715	MicroRNA-127 Inhibits Lung Inflammation by Targeting IgG Fcgamma Receptor I.
664	hsa-mir-203	BIRC5	Laryngeal Neoplasms	22306317	MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin.
665	hsa-mir-205	PTEN	Nasopharyngeal Neoplasms	22306986	MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN.
666	hsa-mir-125b-2	ARID3B	Breast Neoplasms	22307404	miR-125b targets ARID3B in breast cancer cells.
667	hsa-mir-125b-1	ARID3B	Breast Neoplasms	22307404	miR-125b targets ARID3B in breast cancer cells.
668	hsa-mir-135a-1	JAK2	Stomach Neoplasms	22310976	MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation.
669	hsa-mir-135a-2	JAK2	Stomach Neoplasms	22310976	MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation.
670	hsa-mir-520b	MEKK2	Carcinoma, Hepatocellular	22319632	MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1.
671	hsa-mir-520b	CCND1	Carcinoma, Hepatocellular	22319632	MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1.
672	hsa-mir-30c-2	HMBOX1	Carcinoma, Hepatocellular	22320217	miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1.
673	hsa-mir-30c-1	HMBOX1	Carcinoma, Hepatocellular	22320217	miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1.
674	hsa-mir-182	CREB1	Stomach Neoplasms	22325466	MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma.
675	hsa-mir-195	BCL2	Breast Neoplasms	22328513	miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap
676	hsa-mir-24-2	BCL2	Breast Neoplasms	22328513	miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap
677	hsa-mir-365b	BCL2	Breast Neoplasms	22328513	miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap
678	hsa-mir-29b-1	ATP1B1	Breast Neoplasms	22330642	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
679	hsa-mir-513a-1	ATP1B1	Breast Neoplasms	22330642	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
680	hsa-mir-29a	ATP1B1	Breast Neoplasms	22330642	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
681	hsa-mir-513a-2	ATP1B1	Breast Neoplasms	22330642	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
682	hsa-mir-29c	ATP1B1	Breast Neoplasms	22330642	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
683	hsa-mir-29b-2	ATP1B1	Breast Neoplasms	22330642	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
684	hsa-mir-32	REV3L	Lung Neoplasms	22349819	REV3L 3'UTR 460 T>C polymorphism in microRNA(miR-25/32) target sites contributes to lung cancer susceptibility.
685	hsa-mir-25	REV3L	Lung Neoplasms	22349819	REV3L 3'UTR 460 T>C polymorphism in microRNA(miR-25/32) target sites contributes to lung cancer susceptibility.
686	hsa-mir-212	PTCH1	Carcinoma, Non-Small-Cell Lung	22357618	MiR-212 displays Tumor Promoting properties in NSCLC Cells and targets the Hedgehog Pathway Receptor PTCH1.
687	hsa-mir-138-2	CCND3	Carcinoma, Hepatocellular	22362728	MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma.
688	hsa-mir-138-1	CCND3	Carcinoma, Hepatocellular	22362728	MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma.
689	hsa-mir-1-1	SLUG	Prostatic Neoplasms	22370643	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
690	hsa-mir-1-2	SLUG	Prostatic Neoplasms	22370643	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
691	hsa-mir-200b	SLUG	Prostatic Neoplasms	22370643	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
692	hsa-mir-200a	SLUG	Prostatic Neoplasms	22370643	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
693	hsa-mir-200c	SLUG	Prostatic Neoplasms	22370643	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
694	hsa-mir-199b	PODXL	Leukemia, Myeloid, Acute	22374871	miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia.
695	hsa-mir-199b	DDR1	Leukemia, Myeloid, Acute	22374871	miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia.
696	hsa-mir-18a	THBS1	Hemangiosarcoma	22383169	The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
697	hsa-mir-19a	THBS1	Hemangiosarcoma	22383169	The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
698	hsa-mir-20a	THBS1	Hemangiosarcoma	22383169	The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
699	hsa-mir-17	THBS1	Hemangiosarcoma	22383169	The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
700	hsa-mir-92a-1	THBS1	Hemangiosarcoma	22383169	The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
701	hsa-mir-19b-1	THBS1	Hemangiosarcoma	22383169	The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
702	hsa-mir-409	PHF10	Stomach Neoplasms	22388101	MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer.
703	hsa-mir-328	IGF1R	Hypertension	22392900	The MicroRNA-328 Regulates Hypoxic Pulmonary Hypertension by Targeting at Insulin Growth Factor 1 Receptor and L-Type Calcium Channel-alpha1C.
704	hsa-mir-328	CACNA1C	Hypertension	22392900	The MicroRNA-328 Regulates Hypoxic Pulmonary Hypertension by Targeting at Insulin Growth Factor 1 Receptor and L-Type Calcium Channel-alpha1C.
705	hsa-mir-133b	EGFR	Prostatic Neoplasms	22407299	microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor.
706	hsa-mir-133a-2	EGFR	Prostatic Neoplasms	22407299	microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor.
707	hsa-mir-133a-1	EGFR	Prostatic Neoplasms	22407299	microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor.
708	hsa-mir-200c	ZEB1	Colorectal Neoplasms	22407310	miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1.miR-200c inhibits metastatic ability by targeting ZEB1 in colon cancer cells SW480/620 and suggested that modulation of miR-200c could serve as therapeutic to
709	hsa-mir-125b-1	MAZ	Glioblastoma	22415301	Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma.
710	hsa-mir-125b-2	MAZ	Glioblastoma	22415301	Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma.
711	hsa-mir-20a	EPHB4	Pre-Eclampsia	22438230	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
712	hsa-mir-20a	EFNB2	Pre-Eclampsia	22438230	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
713	hsa-mir-20b	EPHB4	Pre-Eclampsia	22438230	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
714	hsa-mir-20b	EFNB2	Pre-Eclampsia	22438230	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
715	hsa-mir-17	EPHB4	Pre-Eclampsia	22438230	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
716	hsa-mir-17	EFNB2	Pre-Eclampsia	22438230	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
717	hsa-mir-135a-1	HOXA10	Breast Neoplasms	22439757	miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10.
718	hsa-mir-135a-2	HOXA10	Breast Neoplasms	22439757	miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10.
719	hsa-mir-128-2	p70S6K1	Glioma	22442669	miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1.
720	hsa-mir-128-1	p70S6K1	Glioma	22442669	miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1.
721	hsa-mir-219-1	GPC3	Carcinoma, Hepatocellular	22449976	MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3.
722	hsa-mir-219-2	GPC3	Carcinoma, Hepatocellular	22449976	MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3.
723	hsa-mir-20a	TNKS2	Uterine Cervical Neoplasms	22449978	miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells.
724	hsa-mir-23a	MTSS	Colorectal Neoplasms	22455847	MiR-23a expression promotes colon carcinoma cell growth, invasion and metastasis through inhibition of MTSS gene.
725	hsa-mir-320a	CTNNB1	Colorectal Neoplasms	22459450	MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin.
726	hsa-mir-125b-1	ERBB2	Endometrial Neoplasms	22460089	MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2.
727	hsa-mir-125b-2	ERBB2	Endometrial Neoplasms	22460089	MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2.
728	hsa-mir-21	SERPINI1	Stomach Neoplasms	22464652	MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer.
729	hsa-mir-483	ERK1	Glioma	22465663	MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1.
730	hsa-mir-551a	PRL3	Stomach Neoplasms	22469786	MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
731	hsa-mir-495	PRL3	Stomach Neoplasms	22469786	MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
732	hsa-mir-155	GABRR1	Glioblastoma	22470130	miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors.
733	hsa-mir-145	EGFR	Osteosarcoma	22472569	MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells.
734	hsa-mir-34a	PDGFRA	Glioma	22479456	miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis.
735	hsa-mir-141	PPARA	Hepatitis B	22479552	MicroRNA-141 Represses HBV Replication by Targeting PPARA
736	hsa-mir-22	ERBB3	Lung Neoplasms	22484852	miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3.
737	hsa-mir-183	EZR	Osteosarcoma	22525461	Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin.
738	hsa-mir-143	MACC1	Colorectal Neoplasms	22533346	MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer.
739	hsa-mir-181b-2	CREB1	Stomach Neoplasms	22539488	MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas.
740	hsa-mir-181b-1	CREB1	Stomach Neoplasms	22539488	MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas.
741	hsa-mir-214	TWIST	Cholangiocarcinoma	22540680	Downregulated miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist.
742	hsa-mir-27a	ZBTB10	Breast Neoplasms	22553354	Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer.
743	hsa-mir-19a	CUL5	Uterine Cervical Neoplasms	22561557	MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5.
744	hsa-mir-19b-2	CUL5	Uterine Cervical Neoplasms	22561557	MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5.
745	hsa-mir-19b-1	CUL5	Uterine Cervical Neoplasms	22561557	MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5.
746	hsa-mir-9-2	MMP14	Neuroblastoma	22564723	microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells.
747	hsa-mir-9-1	MMP14	Neuroblastoma	22564723	microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells.
748	hsa-mir-9-3	MMP14	Neuroblastoma	22564723	microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells.
749	hsa-mir-10b	SDC1	Breast Neoplasms	22573479	Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.
750	hsa-mir-139	IGF1R	Colorectal Neoplasms	22580051	MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor.
751	hsa-mir-181a-2	KLF6	Stomach Neoplasms	22581522	MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6.
752	hsa-mir-181a-1	KLF6	Stomach Neoplasms	22581522	MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6.
753	hsa-mir-381	ID1	Lung Neoplasms	22592211	MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma.
754	hsa-mir-103a-1	DAPK	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
755	hsa-mir-103b-1	DAPK	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
756	hsa-mir-103a-2	DAPK	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
757	hsa-mir-103b-2	DAPK	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
758	hsa-mir-107	DAPK	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
759	hsa-mir-103a-1	KLF4	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
760	hsa-mir-103b-1	KLF4	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
761	hsa-mir-103a-2	KLF4	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
762	hsa-mir-103b-2	KLF4	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
763	hsa-mir-107	KLF4	Colorectal Neoplasms	22593189	miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
764	hsa-mir-101-2	EZH2	Carcinoma, Renal Cell	22609199	The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
765	hsa-mir-101-1	EZH2	Carcinoma, Renal Cell	22609199	The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
766	hsa-mir-10a	CHL1	Uterine Cervical Neoplasms	22634495	MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells.
767	hsa-mir-139	RAP1B	Colorectal Neoplasms	22642900	Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation.
768	hsa-mir-23b	TAB2	Inflammation	22660635	The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-a.
769	hsa-mir-23b	TAB3	Inflammation	22660635	The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-a.
770	hsa-mir-23b	CHUK	Inflammation	22660635	The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-a.
771	hsa-mir-499a	ETS1	Carcinoma, Hepatocellular	22664953	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
772	hsa-mir-1-2	ETS1	Carcinoma, Hepatocellular	22664953	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
773	hsa-mir-1-1	ETS1	Carcinoma, Hepatocellular	22664953	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
774	hsa-mir-499b	ETS1	Carcinoma, Hepatocellular	22664953	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
775	hsa-mir-34a	Notch1	Glioma	22684560	MicroRNA-34a inhibits human brain glioma cell growth by down-regulation of Notch1.
776	hsa-mir-34a	Notch1	Urinary Bladder Neoplasms	22684561	microRNA-34a inhibit cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1.
777	hsa-mir-590	TGFBR2	Carcinoma, Hepatocellular	22684895	MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-beta RII.
778	hsa-mir-200c	ZEB1	Leiomyoma	22685266	miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.
779	hsa-mir-200c	ZEB2	Leiomyoma	22685266	miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.
780	hsa-mir-200c	BEGFA	Leiomyoma	22685266	miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.
781	hsa-mir-200c	TIMP2	Leiomyoma	22685266	miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.
782	hsa-mir-200c	FBLN5	Leiomyoma	22685266	miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.
783	hsa-mir-143	GCK	Colonic Neoplasms	22691140	microRNA-143 down-regulates Hexokinase 2 in colon cancer cells.
784	hsa-mir-125b-1	STARD13	Breast Neoplasms	22693547	MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells.
785	hsa-mir-125b-2	STARD13	Breast Neoplasms	22693547	MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells.
786	hsa-mir-30c-2	KRAS	Breast Neoplasms	22701724	miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein.
787	hsa-mir-30c-1	KRAS	Breast Neoplasms	22701724	miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein.
788	hsa-mir-7-1	HoxB3	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
789	hsa-mir-218-1	HoxB3	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
790	hsa-mir-7-2	HoxB3	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
791	hsa-mir-7-3	HoxB3	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
792	hsa-mir-218-2	HoxB3	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
793	hsa-mir-23b	PRDX3	Prostatic Neoplasms	22710126	MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer.
794	hsa-mir-497	IGF1R	Colorectal Neoplasms	22710713	MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
795	hsa-mir-632	DNAJB6	Breast Neoplasms	22710984	Micro-RNA-632 downregulates DNAJB6 in breast cancer.
796	hsa-mir-203	BIRC5	Breast Neoplasms	22713668	MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.
797	hsa-mir-203	LASP1	Breast Neoplasms	22713668	MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.
798	hsa-mir-195	BACE1	Alzheimer Disease	22721728	MicroRNA-195 downregulates Alzheimer's disease amyloid-beta production by targeting BACE1.
799	hsa-mir-137	ESRRA	Breast Neoplasms	22723937	MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.
800	hsa-mir-337	STAT3	Carcinoma, Non-Small-Cell Lung	22723956	miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.
801	hsa-mir-337	RAP1A	Carcinoma, Non-Small-Cell Lung	22723956	miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.
802	hsa-mir-17	TP53INP1	Uterine Cervical Neoplasms	22730212	MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells.
803	hsa-mir-138-1	CCND1	Nasopharyngeal Neoplasms	22739938	MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene.
804	hsa-mir-138-2	CCND1	Nasopharyngeal Neoplasms	22739938	MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene.
805	hsa-mir-513a-1	GSTP1	Lung Neoplasms	22749944	miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1.
806	hsa-mir-513a-2	GSTP1	Lung Neoplasms	22749944	miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1.
807	hsa-mir-138-1	VIM	Carcinoma, Renal Cell	22766839	Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
808	hsa-mir-138-2	VIM	Carcinoma, Renal Cell	22766839	Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
809	hsa-mir-218-2	LEF1	Glioblastoma	22766851	MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1.
810	hsa-mir-218-1	LEF1	Glioblastoma	22766851	MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1.
811	hsa-mir-7-1	HOXB5	Urinary Bladder Neoplasms	22768238	A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer.
812	hsa-mir-7-2	HOXB5	Urinary Bladder Neoplasms	22768238	A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer.
813	hsa-mir-7-3	HOXB5	Urinary Bladder Neoplasms	22768238	A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer.
814	hsa-mir-125a	MMP11	Carcinoma, Hepatocellular	22768249	Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF.
815	hsa-mir-125a	VEGFA	Carcinoma, Hepatocellular	22768249	Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF.
816	hsa-mir-21	PTEN	Cholangiocarcinoma	22770403	PTEN and PDCD4 are bona fide targets of microRNA-21 in human cholangiocarcinoma.
817	hsa-mir-21	PDCD4	Cholangiocarcinoma	22770403	PTEN and PDCD4 are bona fide targets of microRNA-21 in human cholangiocarcinoma.
818	hsa-mir-125b-1	JUN	Melanoma	22797068	MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression.
819	hsa-mir-125b-2	JUN	Melanoma	22797068	MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression.
820	hsa-mir-193b	PLAU	Prostatic Neoplasms	22797075	CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
821	hsa-mir-224	PLAU	Breast Neoplasms	22809510	MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells.
822	hsa-mir-1231	RKIP	Carcinoma, Hepatocellular	22824466	A miR-1231 binding site polymorphism (rs17875871) in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility.
823	hsa-mir-10b	RKIP	Breast Neoplasms	22847191	MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis.
824	hsa-mir-31	RhoA	Mouth Neoplasms	22854067	Passenger strand miRNA miR-31* regulates the phenotypes of oral cancer cells by targeting RhoA.
825	hsa-mir-196a-1	RAP1A	Esophageal Neoplasms	22859270	MiR-196a binding-site SNP (rs6573) regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis.
826	hsa-mir-196a-2	RAP1A	Esophageal Neoplasms	22859270	MiR-196a binding-site SNP (rs6573) regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis.
827	hsa-mir-29b-2	C1QTNF6	Breast Neoplasms	22864815	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
828	hsa-mir-29b-1	C1QTNF6	Breast Neoplasms	22864815	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
829	hsa-mir-29b-2	SPARC	Breast Neoplasms	22864815	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
830	hsa-mir-29b-1	SPARC	Breast Neoplasms	22864815	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
831	hsa-mir-29b-2	COL4A2	Breast Neoplasms	22864815	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
832	hsa-mir-29b-1	COL4A2	Breast Neoplasms	22864815	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
833	hsa-mir-502	SET8	Ovarian Neoplasms	22867998	A polymorphism (rs16917496) at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer.
834	hsa-mir-145	NEDD9	Glioblastoma	22869051	NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma.
835	hsa-mir-542	JAG1	Glioma	22871495	The Putative Tumor Suppressor miR-524-5p Directly Targets Jagged-1 and Hes-1 in Glioma.
836	hsa-mir-7-3	FAK	Breast Neoplasms	22876288	MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression.
837	hsa-mir-7-2	FAK	Breast Neoplasms	22876288	MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression.
838	hsa-mir-7-1	FAK	Breast Neoplasms	22876288	MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression.
839	hsa-mir-196a-1	HOXA5	Carcinoma, Non-Small-Cell Lung	22876840	MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.
840	hsa-mir-196a-2	HOXA5	Carcinoma, Non-Small-Cell Lung	22876840	MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.
841	hsa-mir-137	ZNF804A	Schizophrenia	22883350	Candidate schizophrenia gene ZNF804A is a target for hsa-miR-137.
842	hsa-mir-133b	EGFR	Carcinoma, Non-Small-Cell Lung	22883469	MicroRNA-133b Inhibits the Growth of Non-small Cell Lung Cancer by Targeting the Epidermal Growth Factor Receptor.
843	hsa-mir-26a-2	PTEN	Lung Neoplasms	22885155	MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN.
844	hsa-mir-26a-1	PTEN	Lung Neoplasms	22885155	MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN.
845	hsa-mir-203	BIRC5	Carcinoma, Hepatocellular	22886454	miR-203 inhibits proliferation of hepatocellular carcinoma cells by targeting survivin.
846	hsa-mir-335	RB1	Meningioma	22886530	miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas.
847	hsa-mir-195	LATS2	Carcinoma, Hepatocellular	22888524	MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2.
848	hsa-mir-132	TMEM106B	Dementia	22895706	TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways.
849	hsa-mir-212	TMEM106B	Dementia	22895706	TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways.
850	hsa-mir-370	FoxM1	Leukemia, Myeloid, Acute	22900969	The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia.
851	hsa-mir-193a	YY1	Endometrial Neoplasms	22907428	YY1 overexpression was found to be a consequence of miR-193a-5p downregulation through direct miR-193a-5p-YY1 interplay.
852	hsa-mir-642a	DOHH	Prostatic Neoplasms	22908221	Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.
853	hsa-mir-642b	DOHH	Prostatic Neoplasms	22908221	Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.
854	hsa-mir-331	DOHH	Prostatic Neoplasms	22908221	Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.
855	hsa-mir-128-2	CSF1	Ovarian Neoplasms	22909061	Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells.
856	hsa-mir-128-1	CSF1	Ovarian Neoplasms	22909061	Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells.
857	hsa-mir-106a	TGFBR2	Colorectal Neoplasms	22912877	MiR-106a inhibits the expression of transforming growth factor-beta receptor 2 (TGFBR2), leading to increased CRC cell migration and invasion. Importantly, miR-106a expression levels in primary CRCs are correlated with clinical cancer progression.
858	hsa-mir-10b	MICB	Neoplasms	22915757	MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells.
859	hsa-mir-141	SOX17	Esophageal Neoplasms	22921431	Inhibition of SOX17 by MicroRNA-141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer.
860	hsa-mir-183	EZR	Osteosarcoma	22922800	miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells.
861	hsa-mir-16-1	CCND1	Osteosarcoma	22922827	miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma.
862	hsa-mir-15a	CCND1	Osteosarcoma	22922827	miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma.
863	hsa-mir-155	AGTR1	Heart Failure	22939041	Angiotensin Receptor Type 1 Single Nucleotide Polymorphism 1166A/C is Associated With Malignant Arrhythmias and Altered Circulating miR-155 Levels in Patients With Chronic Heart Failure.
864	hsa-mir-124-2	PIK3CA	Carcinoma, Hepatocellular	22940133	MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
865	hsa-mir-124-1	PIK3CA	Carcinoma, Hepatocellular	22940133	MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
866	hsa-mir-203	LASP1	Esophageal Neoplasms	22940702	miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1.
867	hsa-mir-338	CCND1	Hepatitis B	22942717	miR-338-3p Is Down-Regulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 3'-UTR Region of CyclinD1.
868	hsa-mir-155	BCL6	Atherosclerosis	23041630	MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages
869	hsa-mir-141	KEAP1	Ovarian Neoplasms	23045278	miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
870	hsa-mir-145	OCT4	Breast Neoplasms	23049906	MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4
871	hsa-mir-1280	ROCK1	Urinary Bladder Neoplasms	23056431	MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer
872	hsa-mir-122	IGF1R	Breast Neoplasms	23056576	MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R
873	hsa-mir-20a	p21	Leukemia, Myeloid	23059786	HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation
874	hsa-mir-20a	STAT3	Leukemia, Myeloid	23059786	HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation
875	hsa-mir-17	p21	Leukemia, Myeloid	23059786	HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation
876	hsa-mir-17	STAT3	Leukemia, Myeloid	23059786	HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation
877	hsa-mir-153-2	PTEN	Prostatic Neoplasms	23060044	Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer
878	hsa-mir-153-1	PTEN	Prostatic Neoplasms	23060044	Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer
879	hsa-mir-214	CTNNB1	Carcinoma, Hepatocellular	23068095	MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin
880	hsa-mir-124-3	AR	Prostatic Neoplasms	23069658	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells
881	hsa-mir-124-2	AR	Prostatic Neoplasms	23069658	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells
882	hsa-mir-124-1	AR	Prostatic Neoplasms	23069658	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells
883	hsa-mir-511-2	TRIB2	Lung Neoplasms	23071539	miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2
884	hsa-mir-511-1	TRIB2	Lung Neoplasms	23071539	miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2
885	hsa-mir-1297	TRIB2	Lung Neoplasms	23071539	miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2
886	hsa-mir-101-1	STMN1	Breast Neoplasms	23071542	MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1
887	hsa-mir-101-2	STMN1	Breast Neoplasms	23071542	MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1
888	hsa-mir-125a	SIRT7	Carcinoma, Hepatocellular	23079745	SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b
889	hsa-mir-125b-2	SIRT7	Carcinoma, Hepatocellular	23079745	SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b
890	hsa-mir-125b-1	SIRT7	Carcinoma, Hepatocellular	23079745	SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b
891	hsa-mir-34a	Notch1	Breast Neoplasms	23085450	MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1
892	hsa-mir-26a-1	E2F7	Leukemia, Myeloid, Acute	23096114	The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells
893	hsa-mir-26a-2	E2F7	Leukemia, Myeloid, Acute	23096114	The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells
894	hsa-mir-15a	VEGF	Multiple Myeloma	23104180	miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF
895	hsa-mir-16-1	VEGF	Multiple Myeloma	23104180	miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF
896	hsa-mir-16-2	VEGF	Multiple Myeloma	23104180	miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF
897	hsa-mir-429	SOX2	Colorectal Neoplasms	23111103	MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2
898	hsa-mir-29b-2	RNASEL	Leukemia, Myeloid, Chronic-Phase	23113544	Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia
899	hsa-mir-29b-1	RNASEL	Leukemia, Myeloid, Chronic-Phase	23113544	Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia
900	hsa-mir-29a	RNASEL	Leukemia, Myeloid, Chronic-Phase	23113544	Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia
901	hsa-mir-144	PTEN	Nasopharyngeal Neoplasms	23125220	MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN
902	hsa-mir-205	LRRK2	Parkinson Disease	23125283	MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein
903	hsa-mir-197	CTNNB1	Pancreatic Neoplasms	23139153	MiR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin
904	hsa-mir-1-2	SLUG	Lung Neoplasms	23142026	MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties
905	hsa-mir-1-1	SLUG	Lung Neoplasms	23142026	MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties
906	hsa-mir-149	ZBTB2	Stomach Neoplasms	23144691	MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer
907	hsa-mir-550a-2	CPEB4	Carcinoma, Hepatocellular	23145039	MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma
908	hsa-mir-550a-3	CPEB4	Carcinoma, Hepatocellular	23145039	MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma
909	hsa-mir-550a-1	CPEB4	Carcinoma, Hepatocellular	23145039	MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma
910	hsa-mir-100	PLK1	Lung Neoplasms	23151088	MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1
911	hsa-mir-204	BCL2	Stomach Neoplasms	23152059	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer
912	hsa-mir-182	NAMPT	HIV-1	23153509	Down-regulation of NAMPT expression by miR-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation
913	hsa-mir-218-2	LAMA3	Neoplasms, Squamous Cell	23159910	Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma
914	hsa-mir-218-1	LAMA3	Neoplasms, Squamous Cell	23159910	Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma
915	hsa-mir-125b-2	PIK3CD	Uterine Cervical Neoplasms	23160634	MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta
916	hsa-mir-125b-1	PIK3CD	Uterine Cervical Neoplasms	23160634	MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta
917	hsa-mir-195	FASN	Osteosarcoma	23162665	microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN
918	hsa-mir-135a-1	MYC	Carcinoma, Renal Cell	23176581	Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma
919	hsa-mir-135a-2	MYC	Carcinoma, Renal Cell	23176581	Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma
920	hsa-mir-137	CDC42	Lung Neoplasms	23178712	miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6
921	hsa-mir-137	CDK6	Lung Neoplasms	23178712	miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6
922	hsa-mir-137	YB1	Neoplasms	23178914	miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1
923	hsa-mir-367	AKT1	Uterine Cervical Neoplasms	23185040	The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1
924	hsa-mir-302a	AKT1	Uterine Cervical Neoplasms	23185040	The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1
925	hsa-mir-133b	EGFR	Urinary Bladder Neoplasms	23206218	MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer
926	hsa-mir-133a-1	EGFR	Urinary Bladder Neoplasms	23206218	MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer
927	hsa-mir-133a-2	EGFR	Urinary Bladder Neoplasms	23206218	MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer
928	hsa-mir-7-3	IRS2	Melanoma	23206698	miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling
929	hsa-mir-7-2	IRS2	Melanoma	23206698	miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling
930	hsa-mir-7-1	IRS2	Melanoma	23206698	miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling
931	hsa-mir-21	TCF21	Carcinoma, Renal Cell	23206776	miR-21 Downregulated TCF21 to Inhibit KISS1 in Renal Cancer
932	hsa-mir-7-3	YY1	Colorectal Neoplasms	23208495	microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis
933	hsa-mir-7-1	YY1	Colorectal Neoplasms	23208495	microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis
934	hsa-mir-7-2	YY1	Colorectal Neoplasms	23208495	microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis
935	hsa-mir-16-1	Ptgs2	Carcinoma, Hepatocellular	23226427	Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells
936	hsa-mir-16-2	Ptgs2	Carcinoma, Hepatocellular	23226427	Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells
937	hsa-mir-182	SMAD4	Urinary Bladder Neoplasms	23226455	Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer
938	hsa-mir-182	RECK	Urinary Bladder Neoplasms	23226455	Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer
939	hsa-mir-21	PTEN	Carcinoma, Endometrioid	23226804	microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer
940	hsa-mir-383	PRDX3	Medulloblastoma	23227829	MiR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3)
941	hsa-mir-335	BIRC5	Lung Neoplasms	23232114	Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations
942	hsa-mir-596	LGALS3BP	Mouth Neoplasms	23233740	Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer
943	hsa-mir-372	TNFAIP1	Stomach Neoplasms	23242208	microRNA-372 maintains oncogene characteristics by targeting TNFAIP1 and affects NFkB signaling in human gastric carcinoma cells
944	hsa-mir-17	P130	Colorectal Neoplasms	23250421	Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130
945	hsa-mir-218-1	BMI1	Colonic Neoplasms	23255074	MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1
946	hsa-mir-218-2	BMI1	Colonic Neoplasms	23255074	MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1
947	hsa-mir-491	MMP9	Cerebral Infarction	23257658	A functional polymorphism at miR-491-5p binding site in the 3'-UTR of MMP-9 gene confers increased risk for atherosclerotic cerebral infarction in a Chinese population
948	hsa-mir-501	HBXIP	Hepatitis B	23266610	MicroRNA-501 promotes HBV replication by targeting HBXIP
949	hsa-mir-100	mTOR	Urinary Bladder Neoplasms	23270926	MicroRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR
950	hsa-mir-885	CASP3	Head and Neck Neoplasms	23271051	A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer
951	hsa-mir-362	E2F1	Colorectal Neoplasms	23280316	MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer
952	hsa-mir-362	USF2	Colorectal Neoplasms	23280316	MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer
953	hsa-mir-362	PTPN1	Colorectal Neoplasms	23280316	MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer
954	hsa-mir-99a	mTOR	Esophageal Neoplasms	23292834	MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma
955	hsa-mir-100	mTOR	Esophageal Neoplasms	23292834	MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma
956	hsa-mir-196b	MYC	Endometriosis	23293219	miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells
957	hsa-mir-196b	BCL2	Endometriosis	23293219	miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells
958	hsa-mir-133b	FGFR1	Stomach Neoplasms	23296701	miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer
959	hsa-mir-199b	HER2	Breast Neoplasms	23296799	MiR-199b-5p targets HER2 in breast cancer cells
960	hsa-mir-182	PDCD4	Ovarian Neoplasms	23296900	MicroRNA-182 promotes cell growth, invasion and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas
961	hsa-mir-34b	SMAD3	Pancreatic Neoplasms	23305226	MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3
962	hsa-mir-330	CDC42	Colorectal Neoplasms	23337504	miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42
963	hsa-mir-301a	RUNX3	Stomach Neoplasms	23338485	Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer
964	hsa-mir-138-1	EZH2	Lung Neoplasms	23343715	MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer
965	hsa-mir-138-2	EZH2	Lung Neoplasms	23343715	MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer
966	hsa-mir-206	CCND2	Stomach Neoplasms	23348698	MiR-206 inhibits gastric cancer proliferation in part by repressing CyclinD2
967	hsa-mir-30a	PRDM1	Glioma	23348703	PRDM1 is directly targeted by miR-30a-5p and modulates the Wnt/beta-catenin pathway in a Dkk1-dependent manner during glioma growth
968	hsa-mir-26b	PTGS2	Breast Neoplasms	23374284	MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer
969	hsa-mir-195	CCND1	Glioma	23383003	MicroRNA-195 Inhibits the Proliferation of Human Glioma Cells by Directly Targeting Cyclin D1 and Cyclin E1
970	hsa-mir-195	CCNE1	Glioma	23383003	MicroRNA-195 Inhibits the Proliferation of Human Glioma Cells by Directly Targeting Cyclin D1 and Cyclin E1
971	hsa-mir-30a	SEPT7	Glioma	23383034	MiR-30a-5p Antisense Oligonucleotide Suppresses Glioma Cell Growth by Targeting SEPT7
972	hsa-mir-182	FOXF2	Prostatic Neoplasms	23383207	MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer
973	hsa-mir-182	RECK	Prostatic Neoplasms	23383207	MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer
974	hsa-mir-182	MTSS1	Prostatic Neoplasms	23383207	MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer
975	hsa-mir-9-1	CCND1	Stomach Neoplasms	23383271	microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
976	hsa-mir-9-1	ETS1	Stomach Neoplasms	23383271	microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
977	hsa-mir-9-2	CCND1	Stomach Neoplasms	23383271	microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
978	hsa-mir-9-2	ETS1	Stomach Neoplasms	23383271	microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
979	hsa-mir-9-3	CCND1	Stomach Neoplasms	23383271	microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
980	hsa-mir-9-3	ETS1	Stomach Neoplasms	23383271	microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
981	hsa-mir-138-1	SOX4	Ovarian Neoplasms	23389731	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting  SOX4 and HIF-1a
982	hsa-mir-138-2	SOX4	Ovarian Neoplasms	23389731	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting  SOX4 and HIF-1a
983	hsa-mir-138-1	HIF1A	Ovarian Neoplasms	23389731	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting  SOX4 and HIF-1a
984	hsa-mir-138-2	HIF1A	Ovarian Neoplasms	23389731	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting  SOX4 and HIF-1a
985	hsa-mir-145	SOCS7	Urinary Bladder Neoplasms	23392170	socs7, a target gene of microRNA-145, regulates interferon-alpha induction through STAT3 nuclear translocation in bladder cancer cells
986	hsa-mir-367	RYR3	Colorectal Neoplasms	23393343	the functional variant (rs1044129) in the miR-367 binding site of RYR3 may be a potential marker for prognosis in patients following curative surgery for CRC
987	hsa-mir-224	p21	Inflammatory Bowel Diseases	23399735	MicroRNA-224 Negatively Regulates p21 Expression During Late Neoplastic Progression in Inflammatory Bowel Disease
988	hsa-mir-137	KDM1A	Neuroblastoma	23400681	miR-137 directly targets KDM1A mRNA in neuroblastoma cells, and activates cell properties consistent with tumor suppression
989	hsa-mir-140	TGFBR1	Carcinoma, Hepatocellular	23401231	MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma
990	hsa-mir-140	FGF9	Carcinoma, Hepatocellular	23401231	MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma
991	hsa-mir-151b	CCNE1	Nasopharyngeal Neoplasms	23416081	A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma
992	hsa-mir-151a	CCNE1	Nasopharyngeal Neoplasms	23416081	A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma
993	hsa-mir-17	PTEN	Carcinoma, Hepatocellular	23418359	Mature MiR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7, and vimentin in different signal pathways
994	hsa-mir-17	GalNT7	Carcinoma, Hepatocellular	23418359	Mature MiR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7, and vimentin in different signal pathways
995	hsa-mir-17	VIM	Carcinoma, Hepatocellular	23418359	Mature MiR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7, and vimentin in different signal pathways
996	hsa-mir-24-1	PTPN9	Neoplasms	23418360	MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling
997	hsa-mir-24-2	PTPN9	Neoplasms	23418360	MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling
998	hsa-mir-24-1	PTPRF	Neoplasms	23418360	MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling
999	hsa-mir-24-2	PTPRF	Neoplasms	23418360	MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling
1000	hsa-mir-320d-2	RTA	Sarcoma, Kaposi	23418466	Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA
1001	hsa-mir-320d-1	RTA	Sarcoma, Kaposi	23418466	Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA
1002	hsa-mir-498	RTA	Sarcoma, Kaposi	23418466	Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA
1003	hsa-mir-570	B7H1	Stomach Neoplasms	23430453	A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
1004	hsa-mir-146a	WASF2	Stomach Neoplasms	23435376	MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2
1005	hsa-mir-126	ADAM9	Melanoma	23437250	miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma
1006	hsa-mir-126	MMP7	Melanoma	23437250	miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma
1007	hsa-mir-135a-2	PTK2	Neoplasms	23438844	MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
1008	hsa-mir-138-1	PTK2	Neoplasms	23438844	MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
1009	hsa-mir-135a-1	PTK2	Neoplasms	23438844	MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
1010	hsa-mir-138-2	PTK2	Neoplasms	23438844	MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
1011	hsa-mir-145	ADAM17	Carcinoma, Renal Cell	23441135	MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients
1012	hsa-mir-29c	RCC2	Stomach Neoplasms	23442884	MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2
1013	hsa-mir-497	IGF1R	Uterine Cervical Neoplasms	23453369	MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor
1014	hsa-mir-218-2	CAV2	Carcinoma, Renal Cell	23454155	microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway
1015	hsa-mir-218-1	CAV2	Carcinoma, Renal Cell	23454155	microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway
1016	hsa-mir-146a	PRKCE	Thyroid Neoplasms	23457043	MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development
1017	hsa-mir-145	ERG	Prostate Neoplasms	23480797	The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer
1018	hsa-mir-145	HDAC2	Carcinoma, Hepatocellular	23499894	MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer
1019	hsa-mir-16-1	IGF1R	Osteosarcoma	23507142	miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma
1020	hsa-mir-16-2	IGF1R	Osteosarcoma	23507142	miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma
1021	hsa-mir-128-2	Bax	Breast Neoplasms	23526655	Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax
1022	hsa-mir-128-1	Bax	Breast Neoplasms	23526655	Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax
1023	hsa-mir-22	SP1	Stomach Neoplasms	23529765	miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1
1024	hsa-mir-9-3	ITGB1	Breast Neoplasms	23530058	miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition
1025	hsa-mir-9-2	ITGB1	Breast Neoplasms	23530058	miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition
1026	hsa-mir-9-1	ITGB1	Breast Neoplasms	23530058	miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition
1027	hsa-mir-183	DKK3	Prostate Neoplasms	23538390	microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
1028	hsa-mir-183	SMAD4	Prostate Neoplasms	23538390	microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
1029	hsa-mir-200b	CREB1	Glioma	23543137	MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma
1030	hsa-mir-139	MCL1	Glioma	23551751	MiR-139 Inhibits Mcl-1 Expression and Potentiates TMZ-Induced Apoptosis in Glioma
1031	hsa-mir-148a	ROCK1	Carcinoma, Non-Small-Cell Lung	23670799	MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells.
1032	hsa-mir-497	HDGF	Carcinoma, Non-Small-Cell Lung	23673296	Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer.
1033	hsa-mir-150	IGF1R	Pancreatic Neoplasms	23675407	Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R.
1034	hsa-mir-630	IGF1R	Pancreatic Neoplasms	23675407	Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R.
1035	hsa-mir-192-2	SOX4	Esophageal Neoplasms	23677061	miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression.
1036	hsa-mir-339	PRL1	Colorectal Neoplasms	23696794	MiR-339-5p Regulates the Growth, Colony Formation and Metastasis of Colorectal Cancer Cells by Targeting PRL-1.
1037	hsa-mir-146a	STAT1	Hepatitis B	23698745	MicroRNA-146a Feedback Suppresses T Cell Immune Function by Targeting Stat1 in Patients with Chronic Hepatitis B.
1038	hsa-mir-137	RTVP1	Glioblastoma	23714687	MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1.
1039	hsa-mir-135b	CD133	Lung Neoplasms	23715500	A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression.
1040	hsa-mir-135a-2	CD133	Lung Neoplasms	23715500	A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression.
1041	hsa-mir-135a-1	CD133	Lung Neoplasms	23715500	A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression.
1042	hsa-mir-155	MLH1	Pancreatic Neoplasms	23715647	MLH1 as a Direct Target of MiR-155 and a Potential Predictor of Favorable Prognosis in Pancreatic Cancer.
1043	hsa-mir-7-2	SET8	Breast Neoplasms	23720754	MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8.
1044	hsa-mir-7-3	SET8	Breast Neoplasms	23720754	MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8.
1045	hsa-mir-7-1	SET8	Breast Neoplasms	23720754	MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8.
1046	hsa-mir-370	FOXO1	Stomach Neoplasms	23721824	Upregulation of miR-370 contributes to the progression of gastric carcinoma via suppression of FOXO1.
1047	hsa-mir-133a-2	RFFL	Colorectal Neoplasms	23723074	MiR-133a activates the p53/p21 pathway and functions as a tumor suppressor in colorectal cancer by repressing RFFL.
1048	hsa-mir-133a-1	RFFL	Colorectal Neoplasms	23723074	MiR-133a activates the p53/p21 pathway and functions as a tumor suppressor in colorectal cancer by repressing RFFL.
1049	hsa-mir-211	TGFBR2	Head and Neck Neoplasms	23726841	miR-211 promotes the progression of head and neck carcinomas by targeting TGFbeta R2.
1050	hsa-mir-29c	SIRT1	Carcinoma, Hepatocellular	23728341	MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.
1051	hsa-mir-203	BIRC5	Pancreatic Neoplasms	23732815	miR-203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin.
1052	hsa-mir-451a	IKBKB	Carcinoma, Hepatocellular	23740840	miR-451 Inhibits Cell Proliferation in Human Hepatocellular Carcinoma through Direct Suppression of IKK-beta
1053	hsa-mir-181c	CD163	PRRSV Infection	23740977	MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
1054	hsa-mir-181b-2	CD163	PRRSV Infection	23740977	MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
1055	hsa-mir-181b-1	CD163	PRRSV Infection	23740977	MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
1056	hsa-mir-181a-2	CD163	PRRSV Infection	23740977	MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
1057	hsa-mir-181a-1	CD163	PRRSV Infection	23740977	MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
1058	hsa-mir-7-1	XIAP	Uterine Cervical Neoplasms	23742934	MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells.
1059	hsa-mir-7-3	XIAP	Uterine Cervical Neoplasms	23742934	MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells.
1060	hsa-mir-7-2	XIAP	Uterine Cervical Neoplasms	23742934	MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells.
1061	hsa-mir-126	CXCR4	Colonic Neoplasms	23744532	Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4.
1062	hsa-mir-150	P53	Lung Neoplasms	23747308	miR-150 promotes the proliferation of lung cancer cells by targeting P53.
1063	hsa-mir-26a-2	MCL1	Breast Neoplasms	23750239	MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1.
1064	hsa-mir-26a-1	MCL1	Breast Neoplasms	23750239	MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1.
1065	hsa-mir-133a-1	BCL2L1	Osteosarcoma	23756231	microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.
1066	hsa-mir-133a-2	BCL2L1	Osteosarcoma	23756231	microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.
1067	hsa-mir-133a-1	MCL1	Osteosarcoma	23756231	microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.
1068	hsa-mir-133a-2	MCL1	Osteosarcoma	23756231	microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.
1069	hsa-mir-223	PARP1	Barrett Esophagus	23757351	MicroRNA 223 is Up-regulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1.
1070	hsa-mir-199a-2	SIRT1	HCMV Infection	23760629	MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS.
1071	hsa-mir-199a-1	SIRT1	HCMV Infection	23760629	MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS.
1072	hsa-mir-199a-2	NOS3	HCMV Infection	23760629	MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS.
1073	hsa-mir-199a-1	NOS3	HCMV Infection	23760629	MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS.
1074	hsa-mir-124-2	CDK4	Glioma	23761023	miR-124 radiosensitizes human glioma cells by targeting CDK4.
1075	hsa-mir-124-1	CDK4	Glioma	23761023	miR-124 radiosensitizes human glioma cells by targeting CDK4.
1076	hsa-mir-149	FOXM1	Carcinoma, Non-Small-Cell Lung	23762558	miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1.
1077	hsa-mir-17	CCND1	Breast Neoplasms	18695042	A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
1078	hsa-mir-20a	CCND1	Breast Neoplasms	18695042	A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
1079	hsa-mir-146b	MMP16	Glioma	19265686	microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs.
1080	hsa-mir-101-1	EZH2	Stomach Neoplasms 	20712078	miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion
1081	hsa-mir-101-2	EZH2	Stomach Neoplasms 	20712078	miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion
1082	hsa-mir-21	RECK	Osteosarcoma 	20480266	MicroRNA-21 is involved in osteosarcoma cell invasion and migration.
1083	hsa-mir-21	PDCD4	Carcinoma, Squamous Cell	20831814	Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma.
1084	hsa-mir-203	BIRC5	Carcinoma, Hepatocellular	22886454	miR-203 inhibits proliferation of HCC cells by targeting surviving.
1085	hsa-let-7a-1	KRAS	Carcinoma, Non-Small-Cell Lung	18922928	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
1086	hsa-let-7a-2	KRAS	Carcinoma, Non-Small-Cell Lung	18922928	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
1087	hsa-let-7a-3	KRAS	Carcinoma, Non-Small-Cell Lung	18922928	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
1088	hsa-let-7b	KRAS	Carcinoma, Non-Small-Cell Lung	18922928	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
1089	hsa-let-7d	KRAS	Carcinoma, Non-Small-Cell Lung	18922928	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
1090	hsa-let-7g	KRAS	Carcinoma, Non-Small-Cell Lung	18922928	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
1091	hsa-let-7a	HMGA2	Stomach Neoplasms	18413822	Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.
1092	hsa-mir-34a	BCL2	Neuroblastoma	18505919	A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
1093	hsa-mir-34a	MYCN	Neuroblastoma	18505919	A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
1094	hsa-mir-372	LATS2	Testicular Neoplasms	16564011	A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.
1095	hsa-mir-373	LATS2	Testicular Neoplasms	16564011	A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.
1096	hsa-let-7c	HMGA2	Leiomyoma	17243163	HMGA2 was identified as one of target genes of the let-7 family of miRNAs and has been found to be suppressed by let-7 in vitro.
1097	hsa-mir-125b	BMPR1B	Breast Neoplasms	19738052	A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.
1098	hsa-mir-128	NTRK3	Anxiety Disorders	19370765	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
1099	hsa-mir-485	NTRK3	Anxiety Disorders	19370765	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
1100	hsa-mir-509	NTRK3	Anxiety Disorders	19370765	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
1101	hsa-mir-765	NTRK3	Anxiety Disorders	19370765	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
1102	hsa-mir-148a	NTRK3	Anxiety Disorders	19370765	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
1103	hsa-mir-148b	NTRK3	Anxiety Disorders	19370765	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
1104	hsa-mir-152	NTRK3	Anxiety Disorders	19370765	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
1105	hsa-mir-146a	CFH	Alzheimer Disease	18801740	An NF-kB-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer's disease and in stressed human brain cells.
1106	hsa-mir-17	BIM	Neuroblastoma	18493594	Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM
1107	hsa-mir-17	p21	Neuroblastoma	18493594	Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM
1108	hsa-mir-127	BLIMP1	Burkitt Lymphoma	19530237	B cell differentiation in EBV-positive Burkitt Lymphoma is impaired at post-transcriptional level by miRNA altered expression.
1109	hsa-mir-127	XBP1	Burkitt Lymphoma	19530237	B cell differentiation in EBV-positive Burkitt Lymphoma is impaired at post-transcriptional level by miRNA altered expression.
1110	hsa-mir-182	FOXO1	Breast Neoplasms	19574223	Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells.
1111	hsa-mir-27a	FOXO1	Breast Neoplasms	19574223	Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells.
1112	hsa-mir-96	FOXO1	Breast Neoplasms	19574223	Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells.
1113	hsa-mir-221	p27	Glioma	19424584	Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo.
1114	hsa-mir-222	p27	Glioma	19424584	Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo.
1115	hsa-mir-122	CCNG1	Carcinoma, Hepatocellular	17616664	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.
1116	hsa-mir-106a	E2F1	Colon Neoplasms	18521848	Deregulated expression of miR-106a predicts survival in human colon cancer patients.
1117	hsa-mir-17	E2F1	Colon Neoplasms	18521848	Deregulated expression of miR-106a predicts survival in human colon cancer patients.
1118	hsa-mir-143	ERK5	Lymphoma, B-Cell	17892514	Downregulation of microRNAs-143 and -145 in B-cell malignancies.
1119	hsa-mir-143	ERK5	Lymphoma, B-Cell	17892514	Downregulation of microRNAs-143 and -145 in B-cell malignancies.
1120	hsa-mir-1-1	HCN4	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1121	hsa-mir-1-2	HCN4	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1122	hsa-mir-133a-1	HCN2	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1123	hsa-mir-133a-2	HCN2	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1124	hsa-mir-133a-1	HCN4	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1125	hsa-mir-133a-2	HCN4	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1126	hsa-mir-133b	HCN2	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1127	hsa-mir-133b	HCN4	Hypertrophy	18458081	Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
1128	hsa-mir-10b	PPARa	Fatty Liver, Non-Alcoholic	19780876	Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD
1129	hsa-mir-510	HTR3E	Irritable Bowel Syndrome	18614545	First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor type 3E gene with diarrhea predominant irritable bowel syndrome.
1130	hsa-let-7a-1	ITGB3	Melanoma	18679415	Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma.
1131	hsa-let-7a-2	ITGB3	Melanoma	18679415	Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma.
1132	hsa-let-7a-3	ITGB3	Melanoma	18679415	Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma.
1133	hsa-mir-145	IRS1	Colon Neoplasms	17827156	Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells.
1134	hsa-mir-210	BCL2L2	Lung Neoplasms	19654003	low expression, targets pro-survival molecules MCL-1 and BCL2L2
1135	hsa-mir-210	MCL1	Lung Neoplasms	19654003	low expression, targets pro-survival molecules MCL-1 and BCL2L2
1136	hsa-mir-21	RECK	Glioma	18591254	MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.
1137	hsa-mir-21	TIMP3	Glioma	18591254	MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.
1138	hsa-let-7b	CCND1	Melanoma	18379589	MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth.
1139	hsa-mir-1-1	MET	Rhabdomyosarcoma	19710019	MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development.
1140	hsa-mir-1-2	MET	Rhabdomyosarcoma	19710019	MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development.
1141	hsa-mir-206	MET	Rhabdomyosarcoma	19710019	MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development.
1142	hsa-mir-125a	ELAVL1	Breast Neoplasms	19875930	MicroRNA-125a represses cell growth by targeting HuR in breast cancer
1143	hsa-mir-128	E2F3a	Glioma	18810376	MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a.
1144	hsa-mir-215	CDKN1A/p21	Glioma	18810376	MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a.
1145	hsa-mir-143	DNMT3A	Colorectal Neoplasms	19638978	MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer.
1146	hsa-mir-145	BNIP3	Prostatic Neoplasms	20332243	MicroRNA145 targets BNIP3 and suppresses prostate cancer progression.
1147	hsa-mir-15b	CCNE1	Glioma	19135980	MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells.
1148	hsa-mir-21	MARCKS	Prostatic Neoplasms	19302977	MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.
1149	hsa-mir-21	HNRPK	Glioblastoma 	18829576	MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells.
1150	hsa-mir-21	p63	Glioblastoma 	18829576	MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells.
1151	hsa-mir-21	TGFB	Glioblastoma 	18829576	MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells.
1152	hsa-mir-21	LRRFIP1	Glioblastoma 	19559015	MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.
1153	hsa-mir-21	LRRFIP1	Glioblastoma 	19559015	MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.
1154	hsa-mir-222	MMP1	Carcinoma, Squamous Cell	19487542	MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1(MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cellcarcinoma cell lines.
1155	hsa-mir-222	SOD2	Carcinoma, Squamous Cell	19487542	MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1(MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cellcarcinoma cell lines.
1156	hsa-mir-29a	DNMT3A	Lung Neoplasms	17890317	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
1157	hsa-mir-29a	DNMT3B	Lung Neoplasms	17890317	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
1158	hsa-mir-29b	DNMT3A	Lung Neoplasms	17890317	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
1159	hsa-mir-29b	DNMT3B	Lung Neoplasms	17890317	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
1160	hsa-mir-29c	DNMT3A	Lung Neoplasms	17890317	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
1161	hsa-mir-29c	DNMT3B	Lung Neoplasms	17890317	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
1162	hsa-mir-34a	MET	Glioblastoma 	19773441	MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
1163	hsa-mir-34a	NOTCH1	Glioblastoma 	19773441	MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
1164	hsa-mir-34a	NOTCH1	Glioblastoma 	19773441	MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
1165	hsa-mir-34a	CDK6	Glioblastoma 	19773441	MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
1166	hsa-mir-122	BCL2L2	Carcinoma, Hepatocellular	18692484	miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines.
1167	hsa-mir-15b	BCL2	Stomach Neoplasms 	18449891	miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
1168	hsa-mir-16-1	BCL2	Stomach Neoplasms 	18449891	miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
1169	hsa-mir-16-2	BCL2	Stomach Neoplasms 	18449891	miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
1170	hsa-mir-206	ESR1	Breast Neoplasms	18593897	miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.
1171	hsa-mir-22	ESR1	Breast Neoplasms	19414598	miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA.
1172	hsa-mir-221	CDKN1B	Prostatic Neoplasms	17569667	miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.
1173	hsa-mir-222	CDKN1B	Prostatic Neoplasms	17569667	miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.
1174	hsa-mir-34b	CREB	Leukemia, Myeloid, Acute	19258499	miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia.
1175	hsa-mir-449a	HDAC1	Prostatic Neoplasms	19252524	miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.
1176	hsa-mir-224	API5	Carcinoma, Hepatocellular	18319255	Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target.
1177	hsa-mir-143	KRAS	Colorectal Neoplasms	19137007	miR-143 directly recognize the 3'-untranslated region of KRAS transcripts
1178	hsa-mir-189	SLITRK1	Tourette Syndrome	16224024	Sequence variants in SLITRK1 are associated with Tourette's syndrome.
1179	hsa-mir-206	ESR1	Breast Neoplasms	17312270	The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.
1180	hsa-mir-15a	CCND1	Prostatic Neoplasms	18931683	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.
1181	hsa-mir-15a	WNT3A	Prostatic Neoplasms	18931683	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.
1182	hsa-mir-16-1	CCND1	Prostatic Neoplasms	18931683	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.
1183	hsa-mir-16-1	WNT3A	Prostatic Neoplasms	18931683	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.
1184	hsa-mir-18a	KRAS	Carcinoma, Squamous Cell	19372139	The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras
1185	hsa-mir-200a	ZEB1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1186	hsa-mir-200b	ZEB1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1187	hsa-mir-200c	ZEB1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1188	hsa-mir-429	ZEB1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1189	hsa-mir-141	ZEB1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1190	hsa-mir-205	ZEB1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1191	hsa-mir-200a	SIP1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1192	hsa-mir-200b	SIP1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1193	hsa-mir-200c	SIP1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1194	hsa-mir-429	SIP1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1195	hsa-mir-141	SIP1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1196	hsa-mir-205	SIP1	Breast Neoplasms	18376396	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
1197	hsa-mir-34a	MYCN	Neuroblastoma	18504438	The MYCN oncogene is a direct target of miR-34a.
1198	hsa-mir-126	PIK3R2	Colon Neoplasms	18663744	The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
1199	hsa-mir-27a	MYT1	Breast Neoplasms	18006846	The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.
1200	hsa-mir-27a	ZBTB10	Breast Neoplasms	18006846	The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.
1201	hsa-mir-16-1	CCND1	Lymphoma, Mantle-Cell	18483394	Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.
1202	hsa-mir-155	TP53INP1	Pancreatic Neoplasms	17911264	Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.
1203	hsa-mir-16-1	CAPRIN1	Breast Neoplasms	19250063	Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation
1204	hsa-mir-16-1	HMGA1	Breast Neoplasms	19250063	Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation
1205	hsa-mir-16-2	CAPRIN1	Breast Neoplasms	19250063	Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation
1206	hsa-mir-16-2	HMGA1	Breast Neoplasms	19250063	Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation
1207	hsa-mir-433	FGF20	Parkinson Disease	18252210	Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.